Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer VCMap
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:ribose phosphate
go back to main search page
Accession:CHEBI:26562 term browser browse the term
Synonyms:related_synonym: ribose phosphates


show annotations for term's descendants           Sort by:
 
3',5'-cyclic AMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCA1 ATP binding cassette subfamily A member 1 increases expression
multiple interactions		 ISO Cyclic AMP results in increased expression of ABCA1 mRNA; Cyclic AMP results in increased expression of ABCA1 protein
[HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein		 CTD PMID:20339114 PMID:20655299 NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155 		JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 increases transport
multiple interactions
affects uptake		 EXP
ISO		 ABCC4 protein results in increased transport of Cyclic AMP
Probenecid affects the reaction [ABCC4 protein affects the uptake of Cyclic AMP analog]		 CTD PMID:11856762 PMID:28587784 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475 		JBrowse link
G ADCYAP1 adenylate cyclase activating polypeptide 1 multiple interactions EXP [ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP CTD PMID:7733904 NCBI chr18:904,411...912,172
Ensembl chr18:904,871...912,172 		JBrowse link
G ADIPOQ adiponectin, C1Q and collagen domain containing increases abundance EXP ADIPOQ protein results in increased abundance of Cyclic AMP CTD PMID:18931039 NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463 		JBrowse link
G ADM adrenomedullin multiple interactions
increases abundance		 ISO ADM protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]
ADM protein results in increased abundance of Cyclic AMP; ADM results in increased abundance of Cyclic AMP		 CTD PMID:10374718 PMID:17306419 NCBI chr11:10,305,073...10,307,397
Ensembl chr11:10,305,073...10,307,397 		JBrowse link
G ADRA1B adrenoceptor alpha 1B multiple interactions ISO ADRA1B protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP] CTD PMID:12649302 NCBI chr 5:159,865,086...159,989,205
Ensembl chr 5:159,865,080...159,973,012 		JBrowse link
G ADRB1 adrenoceptor beta 1 multiple interactions
increases abundance
affects abundance		 EXP
ISO		 [3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Bupranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ADRB1 protein polymorphism affects the reaction [[carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; Isoproterenol promotes the reaction [ADRB1 protein results in increased abundance of Cyclic AMP]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]
ADRB1 protein affects the abundance of Cyclic AMP; ADRB1 protein polymorphism affects the abundance of Cyclic AMP
ADRB1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]		 CTD PMID:11562432 PMID:12761341 PMID:14502278 PMID:14730417 PMID:15060759 More... NCBI chr10:114,043,866...114,046,904
Ensembl chr10:114,043,866...114,046,904 		JBrowse link
G ADRB2 adrenoceptor beta 2 multiple interactions
increases chemical synthesis
increases abundance
affects abundance		 ISO
EXP		 [Terbutaline results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; ADRB2 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]
ADRB2 protein polymorphism results in increased chemical synthesis of Cyclic AMP; ADRB2 protein results in increased chemical synthesis of Cyclic AMP
[Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [BRL 37344 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [carvedilol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Isoproterenol results in increased activity of ADRB2 protein] which results in increased chemical synthesis of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metaproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Nadolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Oxprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Practolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Propranolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Sotalol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]
ADRB2 protein results in increased abundance of Cyclic AMP
ADRB2 protein affects the abundance of Cyclic AMP		 CTD PMID:10516654 PMID:10857765 PMID:10952688 PMID:11562432 PMID:12920204 More... NCBI chr 5:148,826,611...148,828,623
Ensembl chr 5:148,826,611...148,828,623 		JBrowse link
G ADRB3 adrenoceptor beta 3 multiple interactions
affects abundance		 EXP 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [[SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP]; [Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP
ADRB3 protein affects the abundance of Cyclic AMP		 CTD PMID:10952688 PMID:14730417 NCBI chr 8:37,962,990...37,966,599
Ensembl chr 8:37,962,990...37,966,599 		JBrowse link
G AHCYL1 adenosylhomocysteinase like 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of AHCYL1 mRNA] CTD PMID:19414516 NCBI chr 1:109,984,765...110,023,742
Ensembl chr 1:109,984,765...110,023,742 		JBrowse link
G AHR aryl hydrocarbon receptor multiple interactions
decreases expression		 ISO
EXP		 AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA
Cyclic AMP results in decreased expression of AHR protein		 CTD PMID:12859982 PMID:32781018 NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152 		JBrowse link
G ALPP alkaline phosphatase, placental multiple interactions EXP [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA CTD PMID:16036225 NCBI chr 2:232,378,751...232,382,889
Ensembl chr 2:232,378,724...232,382,889 		JBrowse link
G ANGPTL4 angiopoietin like 4 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANGPTL4 mRNA] CTD PMID:19414516 NCBI chr19:8,364,155...8,374,370
Ensembl chr19:8,363,289...8,374,370 		JBrowse link
G ANK2 ankyrin 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANK2 mRNA] CTD PMID:19414516 NCBI chr 4:112,705,622...113,383,736
Ensembl chr 4:112,818,032...113,384,221 		JBrowse link
G AQP3 aquaporin 3 (Gill blood group) multiple interactions
increases expression		 EXP N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-aminoethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA] CTD PMID:12542607 NCBI chr 9:33,441,160...33,447,593
Ensembl chr 9:33,441,156...33,447,596 		JBrowse link
G AQP5 aquaporin 5 multiple interactions ISO Chloroquine inhibits the reaction [Cyclic AMP results in decreased expression of AQP5 protein]; Cyclic AMP affects the expression of and results in increased phosphorylation of and results in increased localization of AQP5 protein CTD PMID:15536076 NCBI chr12:49,961,872...49,965,682
Ensembl chr12:49,961,872...49,965,682 		JBrowse link
G ARMH4 armadillo like helical domain containing 4 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ARMH4 mRNA] CTD PMID:19414516 NCBI chr14:57,993,545...58,152,213
Ensembl chr14:57,999,735...58,298,139 		JBrowse link
G ARNT aryl hydrocarbon receptor nuclear translocator multiple interactions ISO Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein] CTD PMID:12859982 NCBI chr 1:150,809,713...150,876,599
Ensembl chr 1:150,809,713...150,876,708 		JBrowse link
G ARRB2 arrestin beta 2 multiple interactions EXP [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein CTD PMID:25191754 NCBI chr17:4,710,632...4,721,497
Ensembl chr17:4,710,596...4,721,499 		JBrowse link
G ATF5 activating transcription factor 5 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ATF5 mRNA] CTD PMID:19414516 NCBI chr19:49,928,906...49,933,935
Ensembl chr19:49,928,702...49,933,935 		JBrowse link
G AVP arginine vasopressin multiple interactions EXP [AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP CTD PMID:20683494 NCBI chr20:3,082,556...3,084,724
Ensembl chr20:3,082,556...3,084,724 		JBrowse link
G AVPR2 arginine vasopressin receptor 2 multiple interactions
increases abundance		 EXP [AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP
AVPR2 protein results in increased abundance of Cyclic AMP		 CTD PMID:20683494 PMID:33638691 NCBI chr  X:153,902,625...153,907,166
Ensembl chr  X:153,902,531...153,907,166 		JBrowse link
G BDNF brain derived neurotrophic factor multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein CTD PMID:33713149 NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058 		JBrowse link
G BRAF B-Raf proto-oncogene, serine/threonine kinase increases activity
multiple interactions		 EXP
ISO		 Cyclic AMP results in increased activity of BRAF protein
[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein		 CTD PMID:21693435 NCBI chr 7:140,713,328...140,924,929
Ensembl chr 7:140,719,327...140,924,929 		JBrowse link
G C1orf115 chromosome 1 open reading frame 115 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RGD1310587 mRNA] CTD PMID:19414516 NCBI chr 1:220,690,363...220,699,153
Ensembl chr 1:220,690,363...220,699,153 		JBrowse link
G C1QTNF5 C1q and TNF related 5 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C1QTNF5 mRNA] CTD PMID:19414516 NCBI chr11:119,338,942...119,346,705
Ensembl chr11:119,338,942...119,340,940 		JBrowse link
G CALCA calcitonin related polypeptide alpha increases abundance
multiple interactions		 EXP
ISO		 CALCA protein modified form results in increased abundance of Cyclic AMP; CALCA protein results in increased abundance of Cyclic AMP
CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]
Isoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]; sevoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]		 CTD PMID:15297469 PMID:17295025 PMID:17306419 PMID:18463244 NCBI chr11:14,966,668...14,972,351
Ensembl chr11:14,966,668...14,972,351 		JBrowse link
G CARM1 coactivator associated arginine methyltransferase 1 multiple interactions
increases phosphorylation		 EXP [Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] CTD PMID:20360387 NCBI chr19:10,871,553...10,923,075
Ensembl chr19:10,871,553...10,923,075 		JBrowse link
G CCKBR cholecystokinin B receptor multiple interactions ISO CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] CTD PMID:11880531 NCBI chr11:6,259,838...6,272,127
Ensembl chr11:6,259,806...6,272,127 		JBrowse link
G CCL3 C-C motif chemokine ligand 3 multiple interactions ISO Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] CTD PMID:9863660 NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169 		JBrowse link
G CCN2 cellular communication network factor 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CCN2 mRNA] CTD PMID:19414516 NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372 		JBrowse link
G CCND1 cyclin D1 multiple interactions ISO
EXP		 [Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein; sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein] CTD PMID:21693435 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 		JBrowse link
G CD3E CD3 epsilon subunit of T-cell receptor complex decreases phosphorylation ISO Cyclic AMP results in decreased phosphorylation of CD3E protein CTD PMID:2824607 NCBI chr11:118,304,730...118,316,173
Ensembl chr11:118,304,730...118,316,175 		JBrowse link
G CD3G CD3 gamma subunit of T-cell receptor complex decreases phosphorylation ISO Cyclic AMP results in decreased phosphorylation of CD3G protein CTD PMID:2824607 NCBI chr11:118,344,344...118,355,161
Ensembl chr11:118,344,344...118,355,161 		JBrowse link
G CDKN1B cyclin dependent kinase inhibitor 1B multiple interactions ISO
EXP		 [Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein] CTD PMID:21693435 NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369 		JBrowse link
G CEBPB CCAAT enhancer binding protein beta increases response to substance ISO CEBPB protein results in increased susceptibility to Cyclic AMP CTD PMID:23097472 NCBI chr20:50,190,583...50,192,690
Ensembl chr20:50,190,830...50,192,668 		JBrowse link
G CFTR CF transmembrane conductance regulator multiple interactions
increases activity		 EXP
ISO		 Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Bicarbonates]; Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Chlorides]
CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]; Cyclic AMP affects the localization of and results in increased activity of CFTR protein; Nitric Oxide inhibits the reaction [CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]]; Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]; Primaquine inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]
Cyclic AMP results in increased activity of CFTR protein
Genistein promotes the reaction [Cyclic AMP results in increased activity of CFTR protein mutant form]		 CTD PMID:11786964 PMID:12529251 PMID:12556293 PMID:12612912 PMID:15229107 More... NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971 		JBrowse link
G CGA glycoprotein hormones, alpha polypeptide multiple interactions
affects secretion
increases abundance		 ISO
EXP		 [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of CGA mRNA
CGA protein affects the secretion of Cyclic AMP
CGA protein results in increased abundance of Cyclic AMP
[CGA protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [CGA protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; DDT inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]		 CTD PMID:8404651 PMID:20378682 PMID:21642635 PMID:23071612 PMID:26895433 More... NCBI chr 6:87,085,498...87,095,106
Ensembl chr 6:87,085,498...87,095,106 		JBrowse link
G CGB3 chorionic gonadotropin subunit beta 3 multiple interactions
increases abundance
increases secretion		 EXP [CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP; Atrazine inhibits the reaction [CGB3 protein results in increased secretion of Cyclic AMP]; Atrazine promotes the reaction [CGB3 protein results in increased abundance of Cyclic AMP]; Colforsin promotes the reaction [CGB3 protein results in increased abundance of Cyclic AMP]; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; Flame Retardants inhibits the reaction [[CGB3 protein co-treated with Colforsin] results in increased abundance of Cyclic AMP]; Flame Retardants inhibits the reaction [Colforsin promotes the reaction [CGB3 protein results in increased abundance of Cyclic AMP]]; hexabromocyclododecane inhibits the reaction [Colforsin promotes the reaction [CGB3 protein results in increased abundance of Cyclic AMP]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atrazine promotes the reaction [CGB3 protein results in increased abundance of Cyclic AMP]] CTD PMID:19541795 PMID:19766106 PMID:20667998 PMID:22461451 PMID:23347875 NCBI chr19:49,022,869...49,024,333
Ensembl chr19:49,022,869...49,024,333 		JBrowse link
G CHSY1 chondroitin sulfate synthase 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CHSY1 mRNA] CTD PMID:19414516 NCBI chr15:101,175,727...101,252,048
Ensembl chr15:101,175,727...101,252,048 		JBrowse link
G CNR1 cannabinoid receptor 1 multiple interactions ISO
EXP		 [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]		 CTD PMID:10422789 PMID:11730719 PMID:17953657 PMID:27429655 NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347 		JBrowse link
G CNR2 cannabinoid receptor 2 multiple interactions EXP (1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CTD PMID:17558435 PMID:27429655 NCBI chr 1:23,870,515...23,913,362
Ensembl chr 1:23,870,515...23,913,362 		JBrowse link
G CNTN1 contactin 1 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA CTD PMID:33713149 NCBI chr12:40,692,439...41,072,415
Ensembl chr12:40,692,439...41,072,415 		JBrowse link
G CP ceruloplasmin multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CP mRNA] CTD PMID:19414516 NCBI chr 3:149,162,414...149,221,829
Ensembl chr 3:149,162,410...149,221,829 		JBrowse link
G CREB1 cAMP responsive element binding protein 1 multiple interactions ISO [Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; [Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] CTD PMID:12859982 PMID:22676303 NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988 		JBrowse link
G CREBBP CREB binding protein multiple interactions EXP CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein] CTD PMID:20360387 NCBI chr16:3,725,054...3,880,713
Ensembl chr16:3,725,054...3,880,713 		JBrowse link
G CRH corticotropin releasing hormone multiple interactions EXP
ISO		 [CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP]
CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Cholera Toxin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Manganese results in increased chemical synthesis of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]		 CTD PMID:2153673 PMID:20702571 NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464 		JBrowse link
G CRHR1 corticotropin releasing hormone receptor 1 multiple interactions EXP [CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] CTD PMID:20702571 NCBI chr17:45,784,320...45,835,828
Ensembl chr17:45,784,280...45,835,828 		JBrowse link
G CRP C-reactive protein multiple interactions ISO Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA] CTD PMID:22117073 NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589 		JBrowse link
G CSF3 colony stimulating factor 3 increases expression EXP Cyclic AMP results in increased expression of CSF3 protein CTD PMID:7540958 NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813 		JBrowse link
G CSK C-terminal Src kinase multiple interactions ISO CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Terbutaline results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]] CTD PMID:1699227 NCBI chr15:74,782,080...74,803,197
Ensembl chr15:74,782,080...74,803,197 		JBrowse link
G CSTB cystatin B multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CSTB mRNA] CTD PMID:19414516 NCBI chr21:43,773,950...43,776,308
Ensembl chr21:43,772,511...43,776,330 		JBrowse link
G CTSA cathepsin A multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CTSA mRNA] CTD PMID:19414516 NCBI chr20:45,891,335...45,898,820
Ensembl chr20:45,890,144...45,898,949 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions EXP [Terbutaline results in increased abundance of Cyclic AMP] which results in increased expression of CXCL8 protein CTD PMID:9258252 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716 		JBrowse link
G CYP11A1 cytochrome P450 family 11 subfamily A member 1 increases expression
multiple interactions		 ISO
EXP		 Cyclic AMP results in increased expression of CYP11A1 mRNA
Cyclic AMP results in increased expression of CYP11A1 mRNA; Cyclic AMP results in increased expression of CYP11A1 protein
myricetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]		 CTD PMID:25576683 PMID:28668616 PMID:29228121 NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646 		JBrowse link
G CYP11B1 cytochrome P450 family 11 subfamily B member 1 increases expression
multiple interactions		 EXP Cyclic AMP results in increased expression of CYP11B1 mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of CYP11B1 mRNA]		 CTD PMID:22172629 NCBI chr 8:142,872,357...142,879,825
Ensembl chr 8:142,872,356...142,879,846 		JBrowse link
G CYP17A1 cytochrome P450 family 17 subfamily A member 1 multiple interactions
increases expression		 EXP
ISO		 [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein
Cyclic AMP results in increased expression of CYP17A1 mRNA		 CTD PMID:23084589 PMID:25576683 NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472 		JBrowse link
G CYP19A1 cytochrome P450 family 19 subfamily A member 1 increases expression
multiple interactions		 EXP Cyclic AMP results in increased expression of CYP19A1 mRNA; Cyclic AMP results in increased expression of CYP19A1 protein
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]		 CTD PMID:29228121 PMID:31953017 NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601 		JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 multiple interactions EXP 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA CTD PMID:32781018 NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536 		JBrowse link
G CYP1B1 cytochrome P450 family 1 subfamily B member 1 increases expression
multiple interactions		 ISO
EXP		 Cyclic AMP results in increased expression of CYP1B1 mRNA; Cyclic AMP results in increased expression of CYP1B1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA
AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer]		 CTD PMID:12859982 PMID:32781018 NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902 		JBrowse link
G CYP2A6 cytochrome P450 family 2 subfamily A member 6 increases expression
multiple interactions		 ISO Cyclic AMP results in increased expression of CYP2A5 mRNA
Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter]; Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; Dactinomycin inhibits the reaction [Cyclic AMP results in increased expression of CYP2A5 mRNA]		 CTD PMID:12754101 PMID:18602936 NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447 		JBrowse link
G CYP51A1 cytochrome P450 family 51 subfamily A member 1 increases expression ISO Cyclic AMP results in increased expression of CYP51 mRNA CTD PMID:25576683 NCBI chr 7:92,112,153...92,134,803
Ensembl chr 7:92,084,987...92,134,803 		JBrowse link
G CYP7B1 cytochrome P450 family 7 subfamily B member 1 decreases expression
decreases activity		 ISO Cyclic AMP results in decreased expression of CYP7B1 mRNA
Cyclic AMP results in decreased activity of CYP7B1 protein		 CTD PMID:12029625 NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737 		JBrowse link
G DAP death associated protein multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DAP mRNA] CTD PMID:19414516 NCBI chr 5:10,679,230...10,761,234
Ensembl chr 5:10,679,230...10,761,234 		JBrowse link
G DDT D-dopachrome tautomerase multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DDT mRNA] CTD PMID:19414516 NCBI chr22:23,971,370...23,980,504
Ensembl chr22:23,971,365...23,979,828 		JBrowse link
G DISC1 DISC1 scaffold protein multiple interactions EXP Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] CTD PMID:16293762 NCBI chr 1:231,626,790...232,041,272
Ensembl chr 1:231,626,790...232,041,272 		JBrowse link
G DKK1 dickkopf WNT signaling pathway inhibitor 1 affects response to substance EXP DKK1 protein affects the susceptibility to Cyclic AMP CTD PMID:21546446 NCBI chr10:52,314,281...52,317,657
Ensembl chr10:52,314,281...52,318,042 		JBrowse link
G DLD dihydrolipoamide dehydrogenase increases abundance ISO DLD protein results in increased abundance of Cyclic AMP CTD PMID:25981801 NCBI chr 7:107,891,107...107,921,198
Ensembl chr 7:107,891,162...107,931,730 		JBrowse link
G DLG4 discs large MAGUK scaffold protein 4 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA CTD PMID:33713149 NCBI chr17:7,187,187...7,220,050
Ensembl chr17:7,187,187...7,219,841 		JBrowse link
G DRD1 dopamine receptor D1 multiple interactions EXP
ISO		 A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]
[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP; A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]; SCH 23390 inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Spiperone inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]		 CTD PMID:8558425 PMID:15711596 NCBI chr 5:175,440,036...175,444,182
Ensembl chr 5:175,440,036...175,444,182 		JBrowse link
G DRD2 dopamine receptor D2 multiple interactions EXP
ISO		 [Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP; CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP]		 CTD PMID:11880531 PMID:17958328 NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691 		JBrowse link
G DRD4 dopamine receptor D4 multiple interactions ISO [3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine binds to and results in decreased activity of DRD4 protein] inhibits the reaction [Naloxone results in increased abundance of Cyclic AMP] CTD PMID:15542745 NCBI chr11:637,269...640,706
Ensembl chr11:637,269...640,706 		JBrowse link
G E2F2 E2F transcription factor 2 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA CTD PMID:33713149 NCBI chr 1:23,505,212...23,531,233
Ensembl chr 1:23,506,438...23,531,233 		JBrowse link
G EGFR epidermal growth factor receptor multiple interactions ISO [Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] CTD PMID:17295779 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628 		JBrowse link
G EGR1 early growth response 1 multiple interactions ISO [[Eugenol results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA CTD PMID:12767924 NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303 		JBrowse link
G EHD2 EH domain containing 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of EHD2 mRNA] CTD PMID:19414516 NCBI chr19:47,713,422...47,743,134
Ensembl chr19:47,713,422...47,743,134 		JBrowse link
G ENDOD1 endonuclease domain containing 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENDOD1 mRNA] CTD PMID:19414516 NCBI chr11:95,089,846...95,132,645
Ensembl chr11:95,089,846...95,132,645 		JBrowse link
G ENO2 enolase 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENO2 mRNA] CTD PMID:19414516 NCBI chr12:6,914,580...6,923,697
Ensembl chr12:6,913,745...6,923,698 		JBrowse link
G EPO erythropoietin increases expression ISO Cyclic AMP results in increased expression of EPO protein CTD PMID:18621143 NCBI chr 7:100,720,468...100,723,700
Ensembl chr 7:100,720,468...100,723,700 		JBrowse link
G ERRFI1 ERBB receptor feedback inhibitor 1 increases expression ISO Cyclic AMP results in increased expression of ERRFI1 mRNA CTD PMID:1472065 NCBI chr 1:8,011,727...8,026,309
Ensembl chr 1:8,004,404...8,026,309 		JBrowse link
G ESR1 estrogen receptor 1 multiple interactions
increases activity		 EXP [Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased activity of ESR1 protein] CTD PMID:19766106 PMID:20360387 NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619 		JBrowse link
G ESR2 estrogen receptor 2 multiple interactions EXP
ISO		 ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]		 CTD PMID:19766106 PMID:20378682 NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112 		JBrowse link
G F2R coagulation factor II thrombin receptor multiple interactions ISO [C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [C186 65 binds to and results in increased activity of F2R protein] which results in decreased chemical synthesis of Cyclic AMP CTD PMID:22207716 NCBI chr 5:76,716,126...76,735,770
Ensembl chr 5:76,716,126...76,735,770 		JBrowse link
G F2RL1 F2R like trypsin receptor 1 multiple interactions EXP Cyclic AMP promotes the reaction [F2RL1 protein results in increased transport of Chlorides] CTD PMID:11804840 NCBI chr 5:76,819,030...76,835,315
Ensembl chr 5:76,818,933...76,835,315 		JBrowse link
G F2RL3 F2R like thrombin or trypsin receptor 3 multiple interactions ISO [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] which results in decreased chemical synthesis of Cyclic AMP CTD PMID:22207716 NCBI chr19:16,888,999...16,892,606
Ensembl chr19:16,888,999...16,892,606 		JBrowse link
G FAM20C FAM20C golgi associated secretory pathway kinase multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FAM20C mRNA] CTD PMID:19414516 NCBI chr 7:192,571...260,772
Ensembl chr 7:192,571...260,772 		JBrowse link
G FCGR2A Fc gamma receptor IIa multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FCGR3 mRNA] CTD PMID:19414516 NCBI chr 1:161,505,457...161,524,048
Ensembl chr 1:161,505,430...161,524,013 		JBrowse link
G FDX1 ferredoxin 1 increases expression
multiple interactions		 ISO Cyclic AMP results in increased expression of FDX1 mRNA
myricetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]		 CTD PMID:28668616 NCBI chr11:110,429,331...110,464,884
Ensembl chr11:110,429,948...110,464,884 		JBrowse link
G FIG4 FIG4 phosphoinositide 5-phosphatase multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FIG4 mRNA] CTD PMID:19414516 NCBI chr 6:109,691,296...109,825,426
Ensembl chr 6:109,690,609...109,878,098 		JBrowse link
G FOS Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression		 EXP
ISO		 [Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA
Cyclic AMP results in increased expression of FOS mRNA		 CTD PMID:10064622 PMID:10711420 NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230 		JBrowse link
G FOXM1 forkhead box M1 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA CTD PMID:33713149 NCBI chr12:2,857,680...2,877,174
Ensembl chr12:2,857,680...2,877,174 		JBrowse link
G FOXO1 forkhead box O1 multiple interactions EXP
ISO		 [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA]
FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]		 CTD PMID:26847930 PMID:31953017 NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641 		JBrowse link
G FSHB follicle stimulating hormone subunit beta multiple interactions
increases abundance
increases secretion		 ISO
EXP		 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of FSHB mRNA; fulvestrant inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Methoxychlor inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]
FSHB protein results in increased secretion of Cyclic AMP
NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]
[FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]		 CTD PMID:8404651 PMID:18535249 PMID:23137853 PMID:23583632 PMID:25549949 More... NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261 		JBrowse link
G FSHR follicle stimulating hormone receptor multiple interactions EXP [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] CTD PMID:26895433 NCBI chr 2:48,962,157...49,154,515
Ensembl chr 2:48,962,157...49,154,527 		JBrowse link
G FZD10 frizzled class receptor 10 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA CTD PMID:33713149 NCBI chr12:130,162,464...130,165,740
Ensembl chr12:130,162,459...130,165,740 		JBrowse link
G G6PC1 glucose-6-phosphatase catalytic subunit 1 multiple interactions ISO [Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]
[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]		 CTD PMID:22676303 PMID:26847930 NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438 		JBrowse link
G GABPB1 GA binding protein transcription factor subunit beta 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GABPB1 mRNA] CTD PMID:19414516 NCBI chr15:50,275,389...50,355,198
Ensembl chr15:50,275,389...50,355,408 		JBrowse link
G GABRA2 gamma-aminobutyric acid type A receptor subunit alpha2 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA CTD PMID:33713149 NCBI chr 4:46,243,548...46,390,300
Ensembl chr 4:46,243,548...46,475,230 		JBrowse link
G GBP2 guanylate binding protein 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GBP2 mRNA] CTD PMID:19414516 NCBI chr 1:89,106,132...89,126,114
Ensembl chr 1:89,106,132...89,150,456 		JBrowse link
G GCG glucagon multiple interactions
increases chemical synthesis
increases abundance		 ISO
EXP		 [GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP
Dietary Fats promotes the reaction [GCG protein results in increased chemical synthesis of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP]
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP		 CTD PMID:6312992 PMID:18669601 PMID:20074626 PMID:25191754 PMID:26964897 NCBI chr 2:162,142,882...162,152,247
Ensembl chr 2:162,142,882...162,152,404 		JBrowse link
G GDNF glial cell derived neurotrophic factor multiple interactions EXP 3,9-bis((ethylthio)methyl)-K-252a inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein; [GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; [GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium; Mazindol inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; vanoxerine inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium] CTD PMID:19647008 PMID:33713149 NCBI chr 5:37,812,677...37,840,041
Ensembl chr 5:37,812,677...37,840,041 		JBrowse link
G GFAP glial fibrillary acidic protein multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA CTD PMID:33713149 NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937 		JBrowse link
G GHRH growth hormone releasing hormone multiple interactions EXP [GH-RH(1-29), desaminotyrosyl(1)-ornithyl(12,21)-alpha-aminobutryic acid(15)-norleucyl(27)-aspartyl(28)-agmatine(29)- binds to and results in increased activity of GHRH protein] which results in increased abundance of Cyclic AMP CTD PMID:22308467 NCBI chr20:37,251,086...37,261,814
Ensembl chr20:37,251,086...37,261,819 		JBrowse link
G GIP gastric inhibitory polypeptide multiple interactions EXP [GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP CTD PMID:25191754 NCBI chr17:48,958,554...48,968,596
Ensembl chr17:48,958,554...48,968,596 		JBrowse link
G GIPR gastric inhibitory polypeptide receptor multiple interactions EXP [GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP CTD PMID:25191754 NCBI chr19:45,668,221...45,683,722
Ensembl chr19:45,668,221...45,683,722 		JBrowse link
G GLI1 GLI family zinc finger 1 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA CTD PMID:33713149 NCBI chr12:57,459,785...57,472,268
Ensembl chr12:57,459,785...57,472,268 		JBrowse link
G GLIPR2 GLI pathogenesis related 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GLIPR2 mRNA] CTD PMID:19414516 NCBI chr 9:36,136,536...36,163,913
Ensembl chr 9:36,136,536...36,163,913 		JBrowse link
G GLP1R glucagon like peptide 1 receptor multiple interactions ISO
EXP		 [GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP		 CTD PMID:18669601 PMID:25191754 NCBI chr 6:39,048,781...39,091,303
Ensembl chr 6:39,048,781...39,091,303 		JBrowse link
G GNAI2 G protein subunit alpha i2 multiple interactions ISO [[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP CTD PMID:20713914 NCBI chr 3:50,227,068...50,263,358
Ensembl chr 3:50,226,292...50,259,362 		JBrowse link
G GNAL G protein subunit alpha L multiple interactions EXP [[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP CTD PMID:15598656 NCBI chr18:11,689,264...11,885,685
Ensembl chr18:11,689,264...11,885,685 		JBrowse link
G GNAS GNAS complex locus multiple interactions EXP
ISO		 [[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP]
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP		 CTD PMID:11895442 PMID:15598656 PMID:23022524 NCBI chr20:58,839,748...58,911,192
Ensembl chr20:58,839,718...58,911,192 		JBrowse link
G GPBAR1 G protein-coupled bile acid receptor 1 multiple interactions ISO
EXP		 [[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP
[Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Lithocholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP		 CTD PMID:17963371 PMID:23022524 NCBI chr 2:218,259,496...218,263,861
Ensembl chr 2:218,259,496...218,263,861 		JBrowse link
G GPC3 glypican 3 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GPC3 mRNA] CTD PMID:19414516 NCBI chr  X:133,535,745...133,985,594
Ensembl chr  X:133,535,745...133,987,100 		JBrowse link
G GREB1L GREB1 like retinoic acid receptor coactivator multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GREB1L mRNA] CTD PMID:19414516 NCBI chr18:21,242,232...21,526,112
Ensembl chr18:21,242,232...21,526,112 		JBrowse link
G GRIA2 glutamate ionotropic receptor AMPA type subunit 2 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA CTD PMID:33713149 NCBI chr 4:157,220,120...157,366,075
Ensembl chr 4:157,204,182...157,366,075 		JBrowse link
G GRIN1 glutamate ionotropic receptor NMDA type subunit 1 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA CTD PMID:33713149 NCBI chr 9:137,139,154...137,168,756
Ensembl chr 9:137,139,154...137,168,756 		JBrowse link
G GRIN2A glutamate ionotropic receptor NMDA type subunit 2A multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA CTD PMID:33713149 NCBI chr16:9,753,404...10,182,908
Ensembl chr16:9,753,404...10,182,928 		JBrowse link
G GRIN2B glutamate ionotropic receptor NMDA type subunit 2B multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA CTD PMID:33713149 NCBI chr12:13,537,337...13,982,134
Ensembl chr12:13,437,942...13,982,002 		JBrowse link
G GRK2 G protein-coupled receptor kinase 2 multiple interactions EXP [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein] CTD PMID:25191754 NCBI chr11:67,266,473...67,286,556
Ensembl chr11:67,266,473...67,286,556 		JBrowse link
G GRN granulin precursor multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GRN mRNA] CTD PMID:19414516 NCBI chr17:44,345,302...44,353,106
Ensembl chr17:44,345,246...44,353,106 		JBrowse link
G GSK3B glycogen synthase kinase 3 beta multiple interactions ISO GSK3B protein affects the reaction [Deamino Arginine Vasopressin results in increased abundance of Cyclic AMP] CTD PMID:20056751 NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994 		JBrowse link
G GTPBP2 GTP binding protein 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GTPBP2 mRNA] CTD PMID:19414516 NCBI chr 6:43,620,494...43,631,333
Ensembl chr 6:43,605,316...43,629,264 		JBrowse link
G GYPC glycophorin C (Gerbich blood group) multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GYPC mRNA] CTD PMID:19414516 NCBI chr 2:126,656,158...126,696,667
Ensembl chr 2:126,656,133...126,696,667 		JBrowse link
G H2BC11 H2B clustered histone 11 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIST2H2BE mRNA] CTD PMID:19414516 NCBI chr 6:27,132,316...27,132,795
Ensembl chr 6:27,125,897...27,132,795 		JBrowse link
G HCAR2 hydroxycarboxylic acid receptor 2 multiple interactions
decreases abundance		 EXP [3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
HCAR2 protein results in decreased abundance of Cyclic AMP		 CTD PMID:17124637 PMID:19223991 PMID:20655299 NCBI chr12:122,701,293...122,703,357
Ensembl chr12:122,701,293...122,703,357 		JBrowse link
G HCAR3 hydroxycarboxylic acid receptor 3 decreases abundance
multiple interactions		 EXP
ISO		 HCAR3 protein results in decreased abundance of Cyclic AMP
[HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Cyclic AMP		 CTD PMID:12563315 PMID:19237584 PMID:20655299 NCBI chr12:122,714,756...122,716,811
Ensembl chr12:122,714,756...122,716,811 		JBrowse link
G HDAC2 histone deacetylase 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HDAC2 mRNA] CTD PMID:19414516 NCBI chr 6:113,933,028...113,971,148
Ensembl chr 6:113,933,028...114,011,308 		JBrowse link
G HDAC6 histone deacetylase 6 affects abundance ISO HDAC6 protein affects the abundance of Cyclic AMP CTD PMID:28887310 NCBI chr  X:48,801,398...48,824,982
Ensembl chr  X:48,801,377...48,824,982 		JBrowse link
G HES3 hes family bHLH transcription factor 3 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA CTD PMID:33713149 NCBI chr 1:6,244,179...6,245,578
Ensembl chr 1:6,244,179...6,245,578 		JBrowse link
G HIVEP2 HIVEP zinc finger 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIVEP2 mRNA] CTD PMID:19414516 NCBI chr 6:142,751,469...142,946,365
Ensembl chr 6:142,751,469...142,956,698 		JBrowse link
G HNF4A hepatocyte nuclear factor 4 alpha multiple interactions ISO Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter] CTD PMID:18602936 NCBI chr20:44,355,699...44,434,596
Ensembl chr20:44,355,700...44,432,845 		JBrowse link
G HOXB1 homeobox B1 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA CTD PMID:33713149 NCBI chr17:48,528,526...48,531,011
Ensembl chr17:48,528,526...48,531,011 		JBrowse link
G HP haptoglobin multiple interactions ISO Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA] CTD PMID:22117073 NCBI chr16:72,054,505...72,061,055
Ensembl chr16:72,054,505...72,061,055 		JBrowse link
G HRH1 histamine receptor H1 multiple interactions EXP 1-Methyl-3-isobutylxanthine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]]; HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]; Triprolidine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]] CTD PMID:2419744 NCBI chr 3:11,137,238...11,263,557
Ensembl chr 3:11,137,093...11,263,557 		JBrowse link
G HRH2 histamine receptor H2 increases abundance
multiple interactions		 EXP HRH2 protein results in increased abundance of Cyclic AMP
[Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cyclic AMP; [Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; [Histamine binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cimetidine]; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in increased activity of HRH2 protein] which results in increased abundance of Histamine]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]; HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]		 CTD PMID:9187264 PMID:9681472 PMID:15843518 NCBI chr 5:175,658,071...175,710,756
Ensembl chr 5:175,658,030...175,710,756 		JBrowse link
G HRH3 histamine receptor H3 multiple interactions ISO [imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] CTD PMID:21276809 NCBI chr20:62,214,960...62,220,278
Ensembl chr20:62,214,960...62,220,278 		JBrowse link
G HSD3B1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 increases expression ISO Cyclic AMP results in increased expression of HSD3B1 mRNA CTD PMID:25576683 NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054 		JBrowse link
G HSD3B2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 increases expression EXP Cyclic AMP results in increased expression of HSD3B2 mRNA CTD PMID:18490834 NCBI chr 1:119,414,931...119,423,034
Ensembl chr 1:119,414,931...119,423,035 		JBrowse link
G HTR1A 5-hydroxytryptamine receptor 1A multiple interactions EXP [JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] CTD PMID:11356925 PMID:20580787 NCBI chr 5:63,957,874...63,962,445
Ensembl chr 5:63,957,874...63,962,507 		JBrowse link
G HTR1B 5-hydroxytryptamine receptor 1B multiple interactions EXP HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] CTD PMID:11134654 NCBI chr 6:77,460,924...77,463,491
Ensembl chr 6:77,460,924...77,463,491 		JBrowse link
G HTR6 5-hydroxytryptamine receptor 6 increases abundance
multiple interactions		 ISO HTR6 protein results in increased abundance of Cyclic AMP
Serotonin promotes the reaction [HTR6 protein results in increased abundance of Cyclic AMP]		 CTD PMID:11406289 NCBI chr 1:19,664,875...19,680,966
Ensembl chr 1:19,664,875...19,680,966 		JBrowse link
G HTR7 5-hydroxytryptamine receptor 7 increases abundance
multiple interactions		 EXP HTR7 results in increased abundance of Cyclic AMP
[3,N-dimethyl-N-(1-methyl-3-(4-methylpiperidin-1-yl)propyl)benzenesulfonamide binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [5-carboxamidotryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Clozapine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] which results in decreased abundance of Cyclic AMP; [Methoxydimethyltryptamines binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Mianserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Ritanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Serotonin binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Spiperone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [volinanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]		 CTD PMID:10720076 PMID:14578406 PMID:19509219 NCBI chr10:90,740,823...90,858,039
Ensembl chr10:90,740,823...90,858,039 		JBrowse link
G HTRA1 HtrA serine peptidase 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HTRA1 mRNA] CTD PMID:19414516 NCBI chr10:122,461,553...122,514,907
Ensembl chr10:122,458,551...122,514,907 		JBrowse link
G IDH2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions		 ISO IDH2 protein mutant form results in increased abundance of Cyclic AMP
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Cyclic AMP]		 CTD PMID:27469509 NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477 		JBrowse link
G IDO1 indoleamine 2,3-dioxygenase 1 multiple interactions EXP 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein CTD PMID:32781018 NCBI chr 8:39,913,891...39,928,790
Ensembl chr 8:39,902,275...39,928,790 		JBrowse link
G IER3 immediate early response 3 multiple interactions
affects response to substance		 ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IER3 mRNA]
IER3 protein affects the susceptibility to Cyclic AMP
[[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP; IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; Pertussis Toxin affects the reaction [IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]]		 CTD PMID:19414516 PMID:20713914 NCBI chr 6:30,743,199...30,744,547
Ensembl chr 6:30,743,199...30,744,548 		JBrowse link
G IFNG interferon gamma multiple interactions EXP 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]] CTD PMID:32781018 NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740 		JBrowse link
G IGFBP1 insulin like growth factor binding protein 1 multiple interactions EXP 2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] CTD PMID:31953017 PMID:32446389 PMID:32781018 NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660 		JBrowse link
G IGFBP5 insulin like growth factor binding protein 5 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IGFBP5 mRNA] CTD PMID:19414516 NCBI chr 2:216,672,105...216,695,549
Ensembl chr 2:216,672,105...216,695,549 		JBrowse link
G IL12A interleukin 12A multiple interactions EXP Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein] CTD PMID:15843518 NCBI chr 3:159,988,835...159,996,019
Ensembl chr 3:159,988,835...159,996,019 		JBrowse link
G IL12B interleukin 12B multiple interactions EXP Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein] CTD PMID:15843518 NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863 		JBrowse link
G IL15RA interleukin 15 receptor subunit alpha multiple interactions
decreases expression		 ISO [Metformin co-treated with Cyclic AMP] results in decreased expression of IL15RA mRNA; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA] CTD PMID:22117073 NCBI chr10:5,948,900...5,978,741
Ensembl chr10:5,943,639...5,978,187 		JBrowse link
G IL17RE interleukin 17 receptor E multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IL17RE mRNA] CTD PMID:19414516 NCBI chr 3:9,902,093...9,916,402
Ensembl chr 3:9,902,612...9,916,402 		JBrowse link
G IL1B interleukin 1 beta multiple interactions
increases abundance		 EXP
ISO		 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Ibuprofen inhibits the reaction [IL1B protein results in increased abundance of Cyclic AMP]; KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; KT 5823 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; Rolipram promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA]; Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA]; Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]		 CTD PMID:8904084 PMID:17709599 PMID:22117073 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G IL1RN interleukin 1 receptor antagonist multiple interactions
increases expression		 ISO Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]; Cyclic AMP promotes the reaction [Metformin results in increased expression of IL1RN mRNA]; Metformin promotes the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] CTD PMID:22117073 NCBI chr 2:113,099,360...113,134,014
Ensembl chr 2:113,099,315...113,134,016 		JBrowse link
G IL4 interleukin 4 increases chemical synthesis
multiple interactions		 EXP IL4 protein results in increased chemical synthesis of Cyclic AMP
Ketoconazole inhibits the reaction [IL4 protein results in increased chemical synthesis of Cyclic AMP]		 CTD PMID:12230500 NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678 		JBrowse link
G IL6 interleukin 6 increases expression ISO Cyclic AMP analog results in increased expression of IL6 mRNA CTD PMID:10469353 NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002 		JBrowse link
G INHBA inhibin subunit beta A increases secretion EXP Cyclic AMP results in increased secretion of INHBA protein CTD PMID:20074812 NCBI chr 7:41,685,114...41,705,406
Ensembl chr 7:41,667,168...41,705,834 		JBrowse link
G INHBE inhibin subunit beta E multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA CTD PMID:33713149 NCBI chr12:57,455,307...57,458,025
Ensembl chr12:57,452,323...57,459,280 		JBrowse link
G IQGAP1 IQ motif containing GTPase activating protein 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IQGAP1 mRNA] CTD PMID:19414516 NCBI chr15:90,388,242...90,502,239
Ensembl chr15:90,388,242...90,502,239 		JBrowse link
G IRF6 interferon regulatory factor 6 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IRF6 mRNA] CTD PMID:19414516 NCBI chr 1:209,785,617...209,806,142
Ensembl chr 1:209,785,617...209,806,175 		JBrowse link
G ITGB1 integrin subunit beta 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ITGB1 mRNA] CTD PMID:19414516 NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792 		JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA CTD PMID:10711420 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048 		JBrowse link
G KCND2 potassium voltage-gated channel subfamily D member 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KCND2 mRNA] CTD PMID:19414516 NCBI chr 7:120,272,908...120,750,337
Ensembl chr 7:120,273,175...120,750,337 		JBrowse link
G KIF15 kinesin family member 15 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KIF15 mRNA] CTD PMID:19414516 NCBI chr 3:44,761,794...44,868,687
Ensembl chr 3:44,761,721...44,873,376 		JBrowse link
G KNG1 kininogen 1 increases abundance ISO KNG1 results in increased abundance of Cyclic AMP CTD PMID:15750287 NCBI chr 3:186,717,359...186,744,410
Ensembl chr 3:186,717,348...186,744,410 		JBrowse link
G LAMP1 lysosomal associated membrane protein 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LAMP1 mRNA] CTD PMID:19414516 NCBI chr13:113,297,239...113,323,672
Ensembl chr13:113,297,239...113,323,672 		JBrowse link
G LEF1 lymphoid enhancer binding factor 1 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA CTD PMID:33713149 NCBI chr 4:108,047,548...108,168,932
Ensembl chr 4:108,047,545...108,168,956 		JBrowse link
G LEP leptin increases abundance
increases expression
multiple interactions		 EXP
ISO		 LEP protein results in increased abundance of Cyclic AMP
Cyclic AMP analog results in increased expression of LEP mRNA
3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile inhibits the reaction [Cyclic AMP analog results in increased expression of LEP mRNA]		 CTD PMID:11342529 PMID:27381457 NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629 		JBrowse link
G LHB luteinizing hormone subunit beta multiple interactions
increases abundance
increases chemical synthesis
affects secretion		 ISO
EXP		 5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of LHB mRNA; [LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]
LHB protein affects the secretion of Cyclic AMP
[LHB protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [LHB protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; DDT inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]		 CTD PMID:2153673 PMID:6430271 PMID:8404651 PMID:23071612 PMID:33638691 NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091 		JBrowse link
G LHCGR luteinizing hormone/choriogonadotropin receptor multiple interactions EXP
ISO		 [CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]		 CTD PMID:19766106 PMID:20378682 NCBI chr 2:48,686,774...48,755,724
Ensembl chr 2:48,686,774...48,755,730 		JBrowse link
G LIPE lipase E, hormone sensitive type increases activity EXP Cyclic AMP results in increased activity of LIPE protein CTD PMID:7155675 NCBI chr19:42,401,514...42,427,388
Ensembl chr19:42,401,514...42,427,388 		JBrowse link
G LMNA lamin A/C multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LMNA mRNA] CTD PMID:19414516 NCBI chr 1:156,082,573...156,140,081
Ensembl chr 1:156,082,573...156,140,081 		JBrowse link
G LURAP1L leucine rich adaptor protein 1 like multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LURAP1L mRNA] CTD PMID:19414516 NCBI chr 9:12,775,020...12,823,060
Ensembl chr 9:12,775,020...12,823,060 		JBrowse link
G MAN1A1 mannosidase alpha class 1A member 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MAN1A mRNA] CTD PMID:19414516 NCBI chr 6:119,177,205...119,350,605
Ensembl chr 6:119,177,205...119,349,761 		JBrowse link
G MAP2 microtubule associated protein 2 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein CTD PMID:33713149 NCBI chr 2:209,424,047...209,734,112
Ensembl chr 2:209,424,047...209,734,118 		JBrowse link
G MC2R melanocortin 2 receptor multiple interactions EXP [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased expression of MC2R mRNA CTD PMID:23084589 NCBI chr18:13,882,044...13,915,707
Ensembl chr18:13,882,044...13,915,707 		JBrowse link
G MSANTD3 Myb/SANT DNA binding domain containing 3 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MSANTD3 mRNA] CTD PMID:19414516 NCBI chr 9:100,427,143...100,451,734
Ensembl chr 9:100,427,143...100,451,734 		JBrowse link
G NDUFB11 NADH:ubiquinone oxidoreductase subunit B11 increases phosphorylation
multiple interactions		 EXP Cyclic AMP results in increased phosphorylation of NDUFB11 protein
Zalcitabine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]; Zidovudine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]		 CTD PMID:17904600 NCBI chr  X:47,142,216...47,145,491
Ensembl chr  X:47,142,071...47,145,466 		JBrowse link
G NGF nerve growth factor multiple interactions
increases expression		 ISO [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA; [Isoproterenol results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA
Cyclic AMP results in increased expression of NGF mRNA		 CTD PMID:2174743 PMID:2853697 NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770 		JBrowse link
G NOG noggin multiple interactions ISO NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] CTD PMID:23137853 NCBI chr17:56,593,699...56,595,611
Ensembl chr17:56,593,699...56,595,611 		JBrowse link
G NPL N-acetylneuraminate pyruvate lyase multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NPL mRNA] CTD PMID:19414516 NCBI chr 1:182,789,773...182,830,384
Ensembl chr 1:182,789,293...182,830,384 		JBrowse link
G NR0B1 nuclear receptor subfamily 0 group B member 1 decreases expression
multiple interactions		 ISO Cyclic AMP results in decreased expression of NR0B1 mRNA
Verapamil promotes the reaction [Cyclic AMP results in decreased expression of NR0B1 mRNA]		 CTD PMID:19822634 NCBI chr  X:30,304,206...30,309,390
Ensembl chr  X:30,304,206...30,309,390 		JBrowse link
G NTAN1 N-terminal asparagine amidase multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NTAN1 mRNA] CTD PMID:19414516 NCBI chr16:15,037,857...15,056,074
Ensembl chr16:15,037,854...15,056,079 		JBrowse link
G OAT ornithine aminotransferase increases activity
multiple interactions
increases expression		 ISO Cyclic AMP results in increased activity of OAT protein
Deoxyglucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Dihydroxyacetone inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased expression of OAT mRNA]; Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glycerol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Inositol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Rhamnose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Xylitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]		 CTD PMID:2824512 PMID:2827574 NCBI chr10:124,397,303...124,418,923
Ensembl chr10:124,397,303...124,418,976 		JBrowse link
G OPRM1 opioid receptor mu 1 multiple interactions EXP [7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [[Naloxone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [[Naltrexone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [clocinnamox binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [nalmefene binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP CTD PMID:11413242 NCBI chr 6:154,010,496...154,246,867
Ensembl chr 6:154,010,496...154,246,867 		JBrowse link
G OR51A2 olfactory receptor family 51 subfamily A member 2 multiple interactions ISO [pelargonic acid results in increased activity of OLFR586 protein] which results in increased abundance of Cyclic AMP; octanoic acid promotes the reaction [[pelargonic acid results in increased activity of OLFR586 protein] which results in increased abundance of Cyclic AMP] CTD PMID:15598656 NCBI chr11:4,954,772...4,955,713
Ensembl chr11:4,954,772...4,955,713 		JBrowse link
G OR5D18 olfactory receptor family 5 subfamily D member 18 multiple interactions ISO [[Eugenol results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA; [Eugenol binds to and results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP; [Eugenol results in increased activity of OLFR73 protein] which results in increased abundance of Cyclic AMP CTD PMID:12767924 PMID:15716417 NCBI chr11:55,819,630...55,820,571
Ensembl chr11:55,819,630...55,820,571 		JBrowse link
G OR6J1 olfactory receptor family 6 subfamily J member 1 multiple interactions EXP
ISO		 [[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP; [[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP
[citronellal results in increased activity of OLFR49 protein] which results in increased abundance of Cyclic AMP		 CTD PMID:15598656 NCBI chr14:22,630,929...22,644,352
Ensembl chr14:22,630,929...22,644,352 		JBrowse link
G OS9 OS9 endoplasmic reticulum lectin multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of OS9 mRNA] CTD PMID:19414516 NCBI chr12:57,694,132...57,721,557
Ensembl chr12:57,693,955...57,721,557 		JBrowse link
G PCK1 phosphoenolpyruvate carboxykinase 1 increases expression
multiple interactions		 ISO Cyclic AMP results in increased expression of PCK1 mRNA
[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; ochratoxin A inhibits the reaction [Cyclic AMP results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]		 CTD PMID:2569870 PMID:8971075 PMID:10446394 PMID:22117073 PMID:22676303 More... NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121 		JBrowse link
G PDE10A phosphodiesterase 10A multiple interactions
increases hydrolysis		 EXP Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP] CTD PMID:10373451 NCBI chr 6:165,327,289...165,988,052
Ensembl chr 6:165,327,287...165,988,117 		JBrowse link
G PDE11A phosphodiesterase 11A increases hydrolysis EXP PDE11A protein results in increased hydrolysis of Cyclic AMP CTD PMID:10725373 NCBI chr 2:177,623,244...178,108,339
Ensembl chr 2:177,623,244...178,108,339 		JBrowse link
G PDE4B phosphodiesterase 4B multiple interactions ISO
EXP		 [[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; [S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP
[Bresol results in decreased activity of PDE4B protein] which results in increased abundance of Cyclic AMP; Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein]		 CTD PMID:16293762 PMID:21266552 PMID:21854221 NCBI chr 1:65,792,510...66,374,579
Ensembl chr 1:65,792,514...66,374,579 		JBrowse link
G PDE7A phosphodiesterase 7A multiple interactions
increases hydrolysis		 EXP 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP] CTD PMID:10618442 PMID:10814504 NCBI chr 8:65,714,334...65,842,064
Ensembl chr 8:65,714,334...65,842,322 		JBrowse link
G PDE7B phosphodiesterase 7B increases hydrolysis
multiple interactions		 EXP
ISO		 PDE7B protein results in increased hydrolysis of Cyclic AMP
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; E 4021 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; vinpocetine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]		 CTD PMID:10618442 PMID:10814504 PMID:10872825 NCBI chr 6:135,851,701...136,195,574
Ensembl chr 6:135,851,701...136,195,574 		JBrowse link
G PDE8A phosphodiesterase 8A multiple interactions
increases metabolic processing
increases hydrolysis		 EXP
ISO		 Dipyridamole inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]
PDE8A protein results in increased hydrolysis of Cyclic AMP
Dipyridamole inhibits the reaction [PDE8A protein results in increased hydrolysis of Cyclic AMP]		 CTD PMID:9671792 PMID:12681444 NCBI chr15:84,980,467...85,139,142
Ensembl chr15:84,980,440...85,139,145 		JBrowse link
G PDE8B phosphodiesterase 8B multiple interactions
increases metabolic processing
increases hydrolysis		 EXP 9-(2-hydroxy-3-nonyl)adenine inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Sildenafil Citrate inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP] CTD PMID:9784418 PMID:12681444 NCBI chr 5:77,180,304...77,428,256
Ensembl chr 5:77,210,449...77,428,256 		JBrowse link
G PDE9A phosphodiesterase 9A increases hydrolysis EXP PDE9A protein results in increased hydrolysis of Cyclic AMP CTD PMID:9624146 NCBI chr21:42,653,621...42,775,509
Ensembl chr21:42,653,621...42,775,509 		JBrowse link
G PDK1 pyruvate dehydrogenase kinase 1 affects abundance
multiple interactions		 ISO PDK1 protein affects the abundance of Cyclic AMP
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP]; tubacin affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubastatin A affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; W 7 affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]		 CTD PMID:28887310 NCBI chr 2:172,555,373...172,724,312
Ensembl chr 2:172,555,373...172,608,669 		JBrowse link
G PEBP1 phosphatidylethanolamine binding protein 1 multiple interactions EXP PEBP1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] CTD PMID:26670611 NCBI chr12:118,136,124...118,145,584
Ensembl chr12:118,136,124...118,145,584 		JBrowse link
G PFN2 profilin 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PFN2 mRNA] CTD PMID:19414516 NCBI chr 3:149,964,904...149,970,895
Ensembl chr 3:149,964,904...150,050,788 		JBrowse link
G PKIA cAMP-dependent protein kinase inhibitor alpha multiple interactions EXP [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein] CTD PMID:29669941 NCBI chr 8:78,516,340...78,605,267
Ensembl chr 8:78,516,340...78,605,267 		JBrowse link
G PLA2G4A phospholipase A2 group IVA increases expression
multiple interactions		 ISO Cyclic AMP results in increased expression of PLA2G4A mRNA; Cyclic AMP results in increased expression of PLA2G4A protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A protein]		 CTD PMID:22187434 NCBI chr 1:186,828,949...186,988,981
Ensembl chr 1:186,828,949...186,988,981 		JBrowse link
G POMC proopiomelanocortin multiple interactions
increases abundance		 ISO [Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP]
POMC protein modified form results in increased abundance of Cyclic AMP
Quercetin analog inhibits the reaction [POMC protein modified form results in increased abundance of Cyclic AMP]		 CTD PMID:4306506 PMID:26586997 NCBI chr 2:25,160,860...25,168,580
Ensembl chr 2:25,160,853...25,168,903 		JBrowse link
G POR cytochrome p450 oxidoreductase increases expression ISO Cyclic AMP results in increased expression of POR mRNA CTD PMID:25576683 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855 		JBrowse link
G PPARGC1A PPARG coactivator 1 alpha multiple interactions
increases expression		 ISO Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]
Cyclic AMP results in increased expression of PPARGC1A mRNA		 CTD PMID:18602936 PMID:22117073 PMID:22676303 NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089 		JBrowse link
G PPP1R14B protein phosphatase 1 regulatory inhibitor subunit 14B multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PPP1R14B mRNA] CTD PMID:19414516 NCBI chr11:64,244,479...64,246,943
Ensembl chr11:64,244,479...64,246,943 		JBrowse link
G PRKACB protein kinase cAMP-activated catalytic subunit beta multiple interactions
affects response to substance		 EXP [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein]; [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] CTD PMID:29669941 NCBI chr 1:84,078,079...84,238,498
Ensembl chr 1:84,078,062...84,238,498 		JBrowse link
G PRKAR1A protein kinase cAMP-dependent type I regulatory subunit alpha multiple interactions EXP [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] CTD PMID:29669941 NCBI chr17:68,413,623...68,551,316
Ensembl chr17:68,511,780...68,551,319 		JBrowse link
G PRKAR2A protein kinase cAMP-dependent type II regulatory subunit alpha multiple interactions ISO Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2A protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2A protein] CTD PMID:11907174 NCBI chr 3:48,744,591...48,847,874
Ensembl chr 3:48,744,597...48,847,874 		JBrowse link
G PRKAR2B protein kinase cAMP-dependent type II regulatory subunit beta multiple interactions ISO Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2B protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2B protein] CTD PMID:11907174 NCBI chr 7:107,044,705...107,161,811
Ensembl chr 7:107,044,705...107,161,811 		JBrowse link
G PRL prolactin multiple interactions
increases secretion		 ISO
EXP		 [Atrazine results in increased abundance of Cyclic AMP] which results in increased secretion of PRL protein
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]
Cyclic AMP results in increased secretion of PRL protein		 CTD PMID:20074812 PMID:23022511 PMID:31953017 PMID:32446389 PMID:32781018 NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826 		JBrowse link
G PROK1 prokineticin 1 affects response to substance EXP PROK1 protein affects the susceptibility to Cyclic AMP CTD PMID:21546446 NCBI chr 1:110,451,149...110,457,358
Ensembl chr 1:110,451,149...110,457,358 		JBrowse link
G PTGDR2 prostaglandin D2 receptor 2 multiple interactions ISO [5-hydroxyindomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [Indomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [sulindac sulfide binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP CTD PMID:15563582 NCBI chr11:60,850,933...60,855,950
Ensembl chr11:60,850,933...60,855,950 		JBrowse link
G PTGER2 prostaglandin E receptor 2 multiple interactions EXP [Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP] CTD PMID:23526216 NCBI chr14:52,314,312...52,328,598
Ensembl chr14:52,314,305...52,328,598 		JBrowse link
G PTGER3 prostaglandin E receptor 3 multiple interactions ISO [Dinoprostone results in increased activity of PTGER3 protein] which results in decreased abundance of Cyclic AMP CTD PMID:10357836 NCBI chr 1:70,852,358...71,047,816
Ensembl chr 1:70,852,353...71,047,816 		JBrowse link
G PTGER4 prostaglandin E receptor 4 multiple interactions EXP [Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP] CTD PMID:23526216 NCBI chr 5:40,679,915...40,746,800
Ensembl chr 5:40,679,915...40,693,735 		JBrowse link
G PTGIR prostaglandin I2 receptor multiple interactions EXP [cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] CTD PMID:11895442 NCBI chr19:46,610,687...46,625,089
Ensembl chr19:46,620,468...46,625,089 		JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Cyclic AMP] CTD PMID:21873648 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922 		JBrowse link
G PTH parathyroid hormone increases abundance ISO PTH protein results in increased abundance of Cyclic AMP CTD PMID:26851681 NCBI chr11:13,492,054...13,496,181
Ensembl chr11:13,492,054...13,496,181 		JBrowse link
G PTHLH parathyroid hormone like hormone increases abundance EXP PTHLH protein results in increased abundance of Cyclic AMP CTD PMID:10600786 NCBI chr12:27,958,084...27,972,733
Ensembl chr12:27,958,084...27,972,733 		JBrowse link
G PTMA prothymosin alpha increases abundance ISO PTMA protein results in increased abundance of Cyclic AMP CTD PMID:9147362 NCBI chr 2:231,708,525...231,713,551
Ensembl chr 2:231,706,895...231,713,551 		JBrowse link
G RAB3B RAB3B, member RAS oncogene family multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RAB3B mRNA] CTD PMID:19414516 NCBI chr 1:51,907,956...51,990,700
Ensembl chr 1:51,907,956...51,990,700 		JBrowse link
G RAP1A RAP1A, member of RAS oncogene family increases activity EXP Cyclic AMP results in increased activity of RAP1A protein CTD PMID:24701590 NCBI chr 1:111,542,009...111,716,691
Ensembl chr 1:111,542,218...111,716,691 		JBrowse link
G RAP1B RAP1B, member of RAS oncogene family multiple interactions ISO
EXP		 [Pentoxifylline results in increased abundance of Cyclic AMP] results in increased abundance of [RAP1B protein binds to Guanosine Triphosphate] CTD PMID:21693435 NCBI chr12:68,610,899...68,671,901
Ensembl chr12:68,610,855...68,671,901 		JBrowse link
G RBFOX3 RNA binding fox-1 homolog 3 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein CTD PMID:33713149 NCBI chr17:79,089,345...79,665,571
Ensembl chr17:79,089,345...79,611,051 		JBrowse link
G RBM12 RNA binding motif protein 12 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RBM12 mRNA] CTD PMID:19414516 NCBI chr20:35,648,925...35,664,900
Ensembl chr20:35,648,925...35,664,956 		JBrowse link
G RGL1 ral guanine nucleotide dissociation stimulator like 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RGL1 mRNA] CTD PMID:19414516 NCBI chr 1:183,636,109...183,928,532
Ensembl chr 1:183,636,085...183,928,532 		JBrowse link
G RMDN3 regulator of microtubule dynamics 3 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RMDN3 mRNA] CTD PMID:19414516 NCBI chr15:40,735,887...40,755,254
Ensembl chr15:40,735,884...40,755,851 		JBrowse link
G S100B S100 calcium binding protein B multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein CTD PMID:33713149 NCBI chr21:46,598,604...46,605,082
Ensembl chr21:46,598,604...46,605,208 		JBrowse link
G SCN2A sodium voltage-gated channel alpha subunit 2 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA CTD PMID:33713149 NCBI chr 2:165,239,414...165,392,304
Ensembl chr 2:165,194,993...165,392,310 		JBrowse link
G SCT secretin multiple interactions
increases abundance		 ISO Epinephrine inhibits the reaction [SCT protein results in increased abundance of Cyclic AMP] CTD PMID:6312992 NCBI chr11:626,309...627,181
Ensembl chr11:626,309...627,181 		JBrowse link
G SDC1 syndecan 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SDC1 mRNA] CTD PMID:19414516 NCBI chr 2:20,200,797...20,225,475
Ensembl chr 2:20,200,797...20,225,433 		JBrowse link
G SLC17A6 solute carrier family 17 member 6 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA CTD PMID:33713149 NCBI chr11:22,338,381...22,379,503
Ensembl chr11:22,338,381...22,379,503 		JBrowse link
G SLC17A7 solute carrier family 17 member 7 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein CTD PMID:33713149 NCBI chr19:49,429,401...49,441,527
Ensembl chr19:49,429,401...49,442,360 		JBrowse link
G SLC22A8 solute carrier family 22 member 8 affects transport EXP SLC22A8 protein affects the transport of Cyclic AMP CTD PMID:11306713 NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841 		JBrowse link
G SLC2A5 solute carrier family 2 member 5 affects expression
multiple interactions		 EXP
ISO		 Cyclic AMP affects the expression of SLC2A5 mRNA
[[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein
[Fructose results in increased abundance of Cyclic AMP] which results in increased stability of SLC2A5 mRNA		 CTD PMID:8037665 PMID:8554516 PMID:12820898 NCBI chr 1:9,035,106...9,094,195
Ensembl chr 1:9,035,106...9,088,478 		JBrowse link
G SLC4A2 solute carrier family 4 member 2 multiple interactions ISO Nitric Oxide inhibits the reaction [SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]]; SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates] CTD PMID:12612912 NCBI chr 7:151,058,200...151,076,527
Ensembl chr 7:151,057,210...151,076,526 		JBrowse link
G SMOC2 SPARC related modular calcium binding 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SMOC2 mRNA] CTD PMID:19414516 NCBI chr 6:168,441,184...168,667,992
Ensembl chr 6:168,441,151...168,673,445 		JBrowse link
G SNX33 sorting nexin 33 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SNX33 mRNA] CTD PMID:19414516 NCBI chr15:75,647,912...75,662,301
Ensembl chr15:75,647,912...75,662,301 		JBrowse link
G SOCS3 suppressor of cytokine signaling 3 multiple interactions EXP 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein] CTD PMID:23782265 NCBI chr17:78,356,778...78,360,925
Ensembl chr17:78,356,778...78,360,077 		JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions EXP WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA] CTD PMID:20685861 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529 		JBrowse link
G SRD5A1 steroid 5 alpha-reductase 1 increases expression ISO Cyclic AMP results in increased expression of SRD5A1 mRNA CTD PMID:25576683 NCBI chr 5:6,633,440...6,674,386
Ensembl chr 5:6,633,427...6,674,386 		JBrowse link
G SST somatostatin multiple interactions EXP [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] CTD PMID:22056254 NCBI chr 3:187,668,912...187,670,394
Ensembl chr 3:187,668,912...187,670,394 		JBrowse link
G SSTR2 somatostatin receptor 2 multiple interactions EXP [64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] CTD PMID:22056254 NCBI chr17:73,165,010...73,176,633
Ensembl chr17:73,165,010...73,176,633 		JBrowse link
G ST6GAL2 ST6 beta-galactoside alpha-2,6-sialyltransferase 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ST6GAL2 mRNA] CTD PMID:19414516 NCBI chr 2:106,801,600...106,887,277
Ensembl chr 2:106,801,600...106,887,108 		JBrowse link
G STAR steroidogenic acute regulatory protein multiple interactions
increases expression		 ISO [Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein; Calcium inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; Diltiazem promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Isradipine promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]]; myricetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; Nifedipine promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR protein]
Cyclic AMP results in increased expression of STAR mRNA; Cyclic AMP results in increased expression of STAR protein		 CTD PMID:19822634 PMID:20100736 PMID:25576683 PMID:28668616 NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992 		JBrowse link
G TAAR1 trace amine associated receptor 1 multiple interactions EXP
ISO		 [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
[3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-chloro-2-(imidazolin-2-yl)isoindoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-phenyl-1,2,3,4-tetrahydroisoquinoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [6-nitroquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Antazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [BE 2254 results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [cirazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [efaroxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Fenoldopam results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Guanabenz results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Histamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Idazoxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Methoxydimethyltryptamines results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [moxonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [N-methylquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [O-methyltyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Quipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [rilmenidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tranylcypromine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tryptamines analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP		 CTD PMID:19725810 NCBI chr 6:132,643,312...132,659,182
Ensembl chr 6:132,643,312...132,659,182 		JBrowse link
G TAS1R2 taste 1 receptor member 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAS1R2 mRNA] CTD PMID:19414516 NCBI chr 1:18,839,599...18,859,660
Ensembl chr 1:18,839,599...18,859,682 		JBrowse link
G TAX1BP1 Tax1 binding protein 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAX1BP1 mRNA] CTD PMID:19414516 NCBI chr 7:27,739,373...27,829,767
Ensembl chr 7:27,739,331...27,844,564 		JBrowse link
G TDO2 tryptophan 2,3-dioxygenase multiple interactions EXP 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA CTD PMID:32781018 NCBI chr 4:155,903,696...155,920,406
Ensembl chr 4:155,854,738...155,920,406 		JBrowse link
G TERT telomerase reverse transcriptase multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA CTD PMID:33713149 NCBI chr 5:1,253,167...1,295,068
Ensembl chr 5:1,253,147...1,295,068 		JBrowse link
G TEX14 testis expressed 14, intercellular bridge forming factor multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TEX14 mRNA] CTD PMID:19414516 NCBI chr17:58,556,678...58,692,045
Ensembl chr17:58,556,678...58,692,055 		JBrowse link
G TFF1 trefoil factor 1 multiple interactions
increases expression		 EXP CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] CTD PMID:20360387 NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535 		JBrowse link
G TGFB3 transforming growth factor beta 3 multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein CTD PMID:33713149 NCBI chr14:75,958,097...75,983,011
Ensembl chr14:75,958,097...75,983,011 		JBrowse link
G TMSB15A thymosin beta 15A multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMSB15B2 mRNA] CTD PMID:19414516 NCBI chr  X:102,513,682...102,516,739
Ensembl chr  X:102,513,682...102,516,739 		JBrowse link
G TMTC4 transmembrane O-mannosyltransferase targeting cadherins 4 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMTC4 mRNA] CTD PMID:19414516 NCBI chr13:100,603,625...100,675,075
Ensembl chr13:100,603,625...100,675,093 		JBrowse link
G TNF tumor necrosis factor decreases expression
multiple interactions		 EXP
ISO		 Cyclic AMP results in decreased expression of TNF protein
Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]		 CTD PMID:8550079 PMID:21266552 PMID:23566200 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336 		JBrowse link
G TNFSF12 TNF superfamily member 12 decreases expression ISO Cyclic AMP results in decreased expression of TNFSF12 mRNA CTD PMID:22117073 NCBI chr17:7,549,058...7,557,881
Ensembl chr17:7,549,058...7,557,890 		JBrowse link
G TRPV4 transient receptor potential cation channel subfamily V member 4 increases expression
multiple interactions		 ISO Cyclic AMP results in increased expression of TRPV4 mRNA; Cyclic AMP results in increased expression of TRPV4 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 protein]		 CTD PMID:22187434 NCBI chr12:109,783,087...109,833,398
Ensembl chr12:109,783,087...109,833,406 		JBrowse link
G TSHB thyroid stimulating hormone subunit beta multiple interactions
increases abundance		 EXP [Cobalt binds to dipyrido(3,2-a-2',3'-c)phenazine binds to N-(2-hydroxybenzyl)glycine analog] inhibits the reaction [TSHB protein results in increased abundance of Cyclic AMP]; [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] CTD PMID:19766106 PMID:21072367 PMID:21123444 NCBI chr 1:115,029,826...115,034,309
Ensembl chr 1:115,029,826...115,034,302 		JBrowse link
G TSHR thyroid stimulating hormone receptor multiple interactions
increases abundance		 EXP [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] CTD PMID:19766106 PMID:21123444 NCBI chr14:80,955,621...81,146,306
Ensembl chr14:80,954,989...81,146,306 		JBrowse link
G TTC6 tetratricopeptide repeat domain 6 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TTC6 mRNA] CTD PMID:19414516 NCBI chr14:37,595,629...37,842,717
Ensembl chr14:37,595,629...38,041,442 		JBrowse link
G TUBB3 tubulin beta 3 class III multiple interactions EXP [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein CTD PMID:33713149 NCBI chr16:89,921,925...89,936,097
Ensembl chr16:89,921,392...89,938,761 		JBrowse link
G UBA5 ubiquitin like modifier activating enzyme 5 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of UBA5 mRNA] CTD PMID:19414516 NCBI chr 3:132,654,430...132,679,794
Ensembl chr 3:132,654,446...132,679,794 		JBrowse link
G VASH1 vasohibin 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH1 mRNA] CTD PMID:19414516 NCBI chr14:76,761,468...76,783,015
Ensembl chr14:76,761,468...76,783,015 		JBrowse link
G VASH2 vasohibin 2 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH2 mRNA] CTD PMID:19414516 NCBI chr 1:212,950,541...212,991,585
Ensembl chr 1:212,950,520...212,992,037 		JBrowse link
G VAT1 vesicle amine transport 1 multiple interactions ISO 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VAT1 mRNA] CTD PMID:19414516 NCBI chr17:43,014,607...43,022,385
Ensembl chr17:43,014,607...43,025,123 		JBrowse link
G VEGFA vascular endothelial growth factor A multiple interactions ISO Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA] CTD PMID:10788502 NCBI chr 6:43,770,209...43,786,487
Ensembl chr 6:43,770,184...43,786,487 		JBrowse link
G VIP vasoactive intestinal peptide multiple interactions
increases abundance		 EXP
ISO		 [VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP
alpha-hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Endrin inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]
VIP protein results in increased abundance of Cyclic AMP; VIP results in increased abundance of Cyclic AMP		 CTD PMID:1657658 PMID:2467674 PMID:7733904 PMID:20732086 NCBI chr 6:152,750,797...152,759,760
Ensembl chr 6:152,750,797...152,759,765 		JBrowse link
G VIPR2 vasoactive intestinal peptide receptor 2 multiple interactions EXP [ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP; [VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP CTD PMID:7733904 NCBI chr 7:159,028,175...159,144,867
Ensembl chr 7:159,028,175...159,144,867 		JBrowse link
G WNT5A Wnt family member 5A multiple interactions EXP WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]; WNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] CTD PMID:20685861 NCBI chr 3:55,465,715...55,505,263
Ensembl chr 3:55,465,715...55,490,539 		JBrowse link
G ZFP36L2 ZFP36 ring finger protein like 2 increases abundance ISO ZFP36L2 protein mutant form results in increased abundance of Cyclic AMP CTD PMID:24830504 NCBI chr 2:43,222,402...43,226,606
Ensembl chr 2:43,222,402...43,226,606 		JBrowse link
3',5'-cyclic GMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCC4 ATP binding cassette subfamily C member 4 increases export
increases transport
multiple interactions		 EXP ABCC4 protein results in increased export of Cyclic GMP
ABCC4 protein results in increased transport of Cyclic GMP
daidzein inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Dipyridamole inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; hesperetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; naringenin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Probenecid inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; Quercetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; resveratrol inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Silymarin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]		 CTD PMID:11856762 PMID:16156793 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475 		JBrowse link
G AGT angiotensinogen multiple interactions
increases abundance		 ISO AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; AGT protein modified form inhibits the reaction [Streptozocin results in decreased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]]
AGT protein modified form results in increased abundance of Cyclic GMP		 CTD PMID:11696475 PMID:28299329 NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576 		JBrowse link
G AGTR2 angiotensin II receptor type 2 multiple interactions ISO [PD 123319 results in decreased activity of AGTR2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] CTD PMID:16982965 NCBI chr  X:116,170,744...116,174,974
Ensembl chr  X:116,170,744...116,174,974 		JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions ISO AKT1 protein inhibits the reaction [Carbon Tetrachloride results in decreased abundance of Cyclic GMP] CTD PMID:12891555 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751 		JBrowse link
G ALDH2 aldehyde dehydrogenase 2 family member multiple interactions EXP ALDH2 protein affects the reaction [Nitroglycerin results in decreased abundance of Cyclic GMP] CTD PMID:17585900 NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532 		JBrowse link
G APOE apolipoprotein E decreases abundance ISO APOE gene mutant form results in decreased abundance of Cyclic GMP CTD PMID:11397713 NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393 		JBrowse link
G BDKRB1 bradykinin receptor B1 multiple interactions ISO [bradykinin, Leu(8)-des-Arg(9)- results in decreased activity of BDKRB1 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] CTD PMID:16982965 NCBI chr14:96,256,210...96,264,763
Ensembl chr14:96,256,210...96,268,967 		JBrowse link
G BDKRB2 bradykinin receptor B2 multiple interactions ISO [icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] CTD PMID:16982965 NCBI chr14:96,204,839...96,244,164
Ensembl chr14:96,204,679...96,244,166 		JBrowse link
G CASP3 caspase 3 multiple interactions ISO Cyclic GMP affects the reaction [Nitric Oxide results in decreased activity of CASP3 protein] CTD PMID:9388267 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509 		JBrowse link
G CAT catalase multiple interactions ISO CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP] CTD PMID:25490417 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CCT7 chaperonin containing TCP1 subunit 7 multiple interactions EXP CCT7 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP] CTD PMID:24213632 NCBI chr 2:73,234,308...73,253,005
Ensembl chr 2:73,233,420...73,253,021 		JBrowse link
G EDN1 endothelin 1 multiple interactions
increases abundance		 ISO Puromycin Aminonucleoside inhibits the reaction [EDN1 protein results in increased abundance of Cyclic GMP] CTD PMID:12972712 NCBI chr 6:12,256,484...12,297,194
Ensembl chr 6:12,290,361...12,297,194 		JBrowse link
G EDN3 endothelin 3 multiple interactions
increases abundance		 ISO Puromycin Aminonucleoside promotes the reaction [EDN3 protein results in increased abundance of Cyclic GMP] CTD PMID:12972712 NCBI chr20:59,300,611...59,325,992
Ensembl chr20:59,300,443...59,325,992 		JBrowse link
G EPO erythropoietin multiple interactions ISO EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [HPH1 gene mutant form results in decreased abundance of Cyclic GMP] CTD PMID:25041251 PMID:25490417 NCBI chr 7:100,720,468...100,723,700
Ensembl chr 7:100,720,468...100,723,700 		JBrowse link
G GCH1 GTP cyclohydrolase 1 affects abundance
increases abundance
multiple interactions		 ISO GCH1 protein affects the abundance of Cyclic GMP
GCH1 gene mutant form results in increased abundance of Cyclic GMP
CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]		 CTD PMID:21963838 PMID:25490417 NCBI chr14:54,842,017...54,902,826
Ensembl chr14:54,842,008...54,902,826 		JBrowse link
G GNRH1 gonadotropin releasing hormone 1 multiple interactions ISO [manganese chloride results in increased chemical synthesis of Cyclic GMP] which results in increased secretion of GNRH1 protein CTD PMID:17110411 PMID:17290048 NCBI chr 8:25,419,258...25,425,040
Ensembl chr 8:25,419,258...25,424,654 		JBrowse link
G GUCY1A1 guanylate cyclase 1 soluble subunit alpha 1 multiple interactions
increases abundance		 EXP [GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP; GUCY1A1 protein mutant form inhibits the reaction [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole results in increased abundance of Cyclic GMP]; GUCY1A1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP]
GUCY1A1 gene mutant form results in increased abundance of Cyclic GMP		 CTD PMID:22171090 PMID:24213632 PMID:25373139 NCBI chr 4:155,666,848...155,737,059
Ensembl chr 4:155,666,726...155,737,059 		JBrowse link
G GUCY1B1 guanylate cyclase 1 soluble subunit beta 1 multiple interactions EXP [GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP CTD PMID:22171090 NCBI chr 4:155,759,021...155,807,811
Ensembl chr 4:155,758,992...155,807,811 		JBrowse link
G HMOX2 heme oxygenase 2 affects abundance ISO HMOX2 affects the abundance of Cyclic GMP CTD PMID:16181104 NCBI chr16:4,474,736...4,510,347
Ensembl chr16:4,474,690...4,510,347 		JBrowse link
G IL12RB2 interleukin 12 receptor subunit beta 2 increases expression ISO Cyclic GMP results in increased expression of IL12RB2 mRNA CTD PMID:12451176 NCBI chr 1:67,307,364...67,398,724
Ensembl chr 1:67,307,364...67,398,724 		JBrowse link
G IL1B interleukin 1 beta multiple interactions
increases abundance		 ISO
EXP		 Halothane inhibits the reaction [IL1B protein results in increased abundance of Cyclic GMP]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP]		 CTD PMID:11506125 PMID:14762100 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions
decreases phosphorylation		 EXP Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]
Cyclic GMP results in decreased phosphorylation of MAP2K1 protein		 CTD PMID:18225537 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656 		JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 decreases phosphorylation
multiple interactions		 EXP Cyclic GMP results in decreased phosphorylation of MAP2K2 protein
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein]		 CTD PMID:18225537 NCBI chr19:4,090,321...4,124,122
Ensembl chr19:4,090,321...4,124,122 		JBrowse link
G MAPK8 mitogen-activated protein kinase 8 increases activity EXP Cyclic GMP analog results in increased activity of MAPK8 protein CTD PMID:11051267 NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360 		JBrowse link
G NOS2 nitric oxide synthase 2 multiple interactions ISO [testosterone enanthate results in increased expression of NOS2 mRNA] which results in increased abundance of Cyclic GMP CTD PMID:20463352 NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529 		JBrowse link
G NOS3 nitric oxide synthase 3 multiple interactions
increases abundance		 ISO NOS3 protein affects the reaction [Ramipril results in increased abundance of Cyclic GMP]
NOS3 protein results in increased abundance of Cyclic GMP		 CTD PMID:11504159 PMID:16891913 NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588 		JBrowse link
G NPPA natriuretic peptide A multiple interactions
increases abundance		 EXP
ISO		 Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]; Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein]
NPPA protein results in increased abundance of Cyclic GMP
AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; carvedilol promotes the reaction [NPPA protein results in increased abundance of Cyclic GMP]; Puromycin Aminonucleoside inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]]		 CTD PMID:9421401 PMID:11696475 PMID:12022755 PMID:12582005 PMID:12972712 More... NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345 		JBrowse link
G NPPC natriuretic peptide C increases chemical synthesis
increases abundance
multiple interactions		 ISO NPPC protein results in increased chemical synthesis of Cyclic GMP
NPPC protein results in increased abundance of Cyclic GMP
Ammonia inhibits the reaction [NPPC protein results in increased chemical synthesis of Cyclic GMP]; Fluoroacetates inhibits the reaction [NPPC protein results in increased abundance of Cyclic GMP]		 CTD PMID:17629948 PMID:18222015 NCBI chr 2:231,921,809...231,926,396
Ensembl chr 2:231,921,809...231,926,396 		JBrowse link
G PDE10A phosphodiesterase 10A multiple interactions
increases hydrolysis		 EXP Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP] CTD PMID:10373451 NCBI chr 6:165,327,289...165,988,052
Ensembl chr 6:165,327,287...165,988,117 		JBrowse link
G PDE11A phosphodiesterase 11A multiple interactions
increases hydrolysis		 EXP 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; Dipyridamole inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; zaprinast inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP] CTD PMID:10725373 NCBI chr 2:177,623,244...178,108,339
Ensembl chr 2:177,623,244...178,108,339 		JBrowse link
G PDE1A phosphodiesterase 1A multiple interactions ISO PDE1A protein inhibits the reaction [Nitroglycerin results in increased abundance of Cyclic GMP] CTD PMID:11696475 NCBI chr 2:182,140,041...182,716,797
Ensembl chr 2:182,139,968...182,523,359 		JBrowse link
G PDE5A phosphodiesterase 5A decreases abundance EXP PDE5A protein results in decreased abundance of Cyclic GMP CTD PMID:10422958 NCBI chr 4:119,494,403...119,628,804
Ensembl chr 4:119,494,397...119,628,804 		JBrowse link
G PDE9A phosphodiesterase 9A increases hydrolysis
multiple interactions		 EXP PDE9A protein results in increased hydrolysis of Cyclic GMP
zaprinast inhibits the reaction [PDE9A protein results in increased hydrolysis of Cyclic GMP]		 CTD PMID:9624146 NCBI chr21:42,653,621...42,775,509
Ensembl chr21:42,653,621...42,775,509 		JBrowse link
G POMC proopiomelanocortin affects abundance ISO POMC protein affects the abundance of Cyclic GMP CTD PMID:11193135 NCBI chr 2:25,160,860...25,168,580
Ensembl chr 2:25,160,853...25,168,903 		JBrowse link
G PTPN12 protein tyrosine phosphatase non-receptor type 12 increases activity ISO Cyclic GMP results in increased activity of PTPN12 protein CTD PMID:12714323 NCBI chr 7:77,537,295...77,640,069
Ensembl chr 7:77,537,295...77,640,069 		JBrowse link
G STK11 serine/threonine kinase 11 multiple interactions EXP STK11 protein promotes the reaction [Histamine results in increased abundance of Cyclic GMP] CTD PMID:21145922 NCBI chr19:1,205,778...1,228,431
Ensembl chr19:1,177,558...1,228,431 		JBrowse link
G TNF tumor necrosis factor multiple interactions
decreases abundance		 ISO 7-(2-(4-(4-nitrobenzene)piperazinyl)ethyl)-1,3-dimethylxanthine inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; KMUP 1 inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; zaprinast inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP] CTD PMID:16754782 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336 		JBrowse link
G VEGFA vascular endothelial growth factor A multiple interactions
increases abundance		 EXP N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [VEGFA protein results in increased abundance of Cyclic GMP] CTD PMID:18575783 NCBI chr 6:43,770,209...43,786,487
Ensembl chr 6:43,770,184...43,786,487 		JBrowse link
G VIM vimentin multiple interactions ISO VIM protein affects the susceptibility to [Acetylcholine co-treated with Cyclic GMP co-treated with Indomethacin] CTD PMID:11588525 NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593 		JBrowse link
G XDH xanthine dehydrogenase multiple interactions ISO [Xanthine co-treated with XDH protein] inhibits the reaction [Nitroprusside results in increased abundance of Cyclic GMP] CTD PMID:17339839 NCBI chr 2:31,334,321...31,414,742
Ensembl chr 2:31,334,321...31,414,742 		JBrowse link
3'-CMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CDIPT CDP-diacylglycerol--inositol 3-phosphatidyltransferase multiple interactions ISO [delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate CTD PMID:2579070 NCBI chr16:29,858,357...29,863,226
Ensembl chr16:29,858,357...29,863,414 		JBrowse link
3'-phospho-5'-adenylyl sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NAT2 N-acetyltransferase 2 multiple interactions EXP [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr 8:18,386,301...18,401,218
Ensembl chr 8:18,391,282...18,401,218 		JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone CTD PMID:20545351 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668 		JBrowse link
G P2RY1 purinergic receptor P2Y1 decreases activity EXP Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein CTD PMID:22273509 NCBI chr 3:152,835,131...152,841,439
Ensembl chr 3:152,835,131...152,841,439 		JBrowse link
G SULT1A1 sulfotransferase family 1A member 1 multiple interactions
increases sulfation		 EXP 2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]
SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate		 CTD PMID:11425650 PMID:16601080 PMID:20545351 NCBI chr16:28,605,258...28,623,375
Ensembl chr16:28,603,944...28,623,625 		JBrowse link
G SULT1A2 sulfotransferase family 1A member 2 multiple interactions EXP [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] CTD PMID:20545351 NCBI chr16:28,591,943...28,597,050
Ensembl chr16:28,591,943...28,597,050 		JBrowse link
G SULT1A3 sulfotransferase family 1A member 3 increases sulfation EXP SULT1A3 protein results in increased sulfation of Phosphoadenosine Phosphosulfate CTD PMID:11425650 NCBI chr16:30,199,255...30,204,310
Ensembl chr16:30,199,228...30,204,310 		JBrowse link
G SULT2A1 sulfotransferase family 2A member 1 multiple interactions EXP [Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol] CTD PMID:15483193 NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315 		JBrowse link
7-methyl-7,8-dihydroguanosine-5'-diphosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G EIF4E eukaryotic translation initiation factor 4E affects binding
multiple interactions		 EXP 7-methylguanosine 5'-diphosphate analog binds to EIF4E protein
7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine-5'-monophosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Guanosine analog inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Quinolones inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Sulfonamides inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]		 CTD PMID:27592390 NCBI chr 4:98,879,276...98,929,133
Ensembl chr 4:98,879,276...98,929,133 		JBrowse link
7-methyl-GTP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G EIF4E eukaryotic translation initiation factor 4E multiple interactions EXP 7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine triphosphate inhibits the reaction [RNA Caps binds to EIF4E protein] CTD PMID:27592390 NCBI chr 4:98,879,276...98,929,133
Ensembl chr 4:98,879,276...98,929,133 		JBrowse link
G EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
affects binding		 EXP 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate] CTD PMID:25940091 NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365 		JBrowse link
G EIF4G1 eukaryotic translation initiation factor 4 gamma 1 multiple interactions
affects binding		 EXP 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate] CTD PMID:25940091 NCBI chr 3:184,314,606...184,335,358
Ensembl chr 3:184,314,495...184,335,358 		JBrowse link
8-(4-chlorophenylthio)-cAMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCA1 ATP binding cassette subfamily A member 1 multiple interactions
increases expression		 ISO Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]]; pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein] CTD PMID:16415093 NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155 		JBrowse link
G ABCB1 ATP binding cassette subfamily B member 1 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB1A mRNA CTD PMID:27160211 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323 		JBrowse link
G ABCB11 ATP binding cassette subfamily B member 11 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB11 mRNA CTD PMID:27160211 NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324 		JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCC2 mRNA CTD PMID:27160211 NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594 		JBrowse link
G ABCG2 ATP binding cassette subfamily G member 2 (Junior blood group) increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCG2 mRNA CTD PMID:27160211 NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628 		JBrowse link
G AKT1 AKT serine/threonine kinase 1 increases phosphorylation ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of AKT1 protein CTD PMID:20610540 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751 		JBrowse link
G BCL2L11 BCL2 like 11 increases expression
increases response to substance		 ISO
EXP		 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 protein
BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP		 CTD PMID:14996839 NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,445 		JBrowse link
G CASP3 caspase 3 increases activity ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased activity of CASP3 protein CTD PMID:14996839 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509 		JBrowse link
G CFL1 cofilin 1 decreases phosphorylation ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased phosphorylation of CFL1 protein CTD PMID:20610540 NCBI chr11:65,854,673...65,858,180
Ensembl chr11:65,823,022...65,862,026 		JBrowse link
G CFTR CF transmembrane conductance regulator multiple interactions EXP [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form CTD PMID:15163550 NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971 		JBrowse link
G CREB1 cAMP responsive element binding protein 1 multiple interactions
increases phosphorylation		 ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of and results in increased activity of CREB1 protein
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of CREB1 protein		 CTD PMID:14741741 PMID:20610540 NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988 		JBrowse link
G NFE2L2 NFE2 like bZIP transcription factor 2 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NFE2L2 mRNA CTD PMID:27160211 NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,227,595...177,392,697 		JBrowse link
G NR1H2 nuclear receptor subfamily 1 group H member 2 multiple interactions ISO NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] CTD PMID:16415093 NCBI chr19:50,376,457...50,383,388
Ensembl chr19:50,329,653...50,383,388 		JBrowse link
G NR1H3 nuclear receptor subfamily 1 group H member 3 multiple interactions ISO NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] CTD PMID:16415093 NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033 		JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I2 mRNA CTD PMID:27160211 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487 		JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I3 mRNA CTD PMID:27160211 NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244 		JBrowse link
G RHOA ras homolog family member A multiple interactions
decreases activity		 ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein]
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased activity of RHOA protein		 CTD PMID:20610540 NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998 		JBrowse link
G RTKN rhotekin multiple interactions ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein] CTD PMID:20610540 NCBI chr 2:74,425,835...74,441,937
Ensembl chr 2:74,425,835...74,442,422 		JBrowse link
G SCNN1A sodium channel epithelial 1 subunit alpha multiple interactions ISO [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] CTD PMID:15161604 NCBI chr12:6,346,847...6,377,359
Ensembl chr12:6,346,843...6,377,730 		JBrowse link
G SCNN1B sodium channel epithelial 1 subunit beta multiple interactions ISO [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] CTD PMID:15161604 NCBI chr16:23,278,231...23,381,294
Ensembl chr16:23,278,231...23,381,294 		JBrowse link
G SCNN1G sodium channel epithelial 1 subunit gamma multiple interactions ISO [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] CTD PMID:15161604 NCBI chr16:23,182,745...23,216,883
Ensembl chr16:23,182,745...23,216,883 		JBrowse link
G SLC10A1 solute carrier family 10 member 1 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLC10A1 mRNA CTD PMID:27160211 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241 		JBrowse link
G SLCO1B3 solute carrier organic anion transporter family member 1B3 increases expression ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1B2 mRNA CTD PMID:27160211 NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911 		JBrowse link
G SNAP25 synaptosome associated protein 25 multiple interactions
affects splicing		 ISO N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP affects the splicing of SNAP25 exon] CTD PMID:22684629 NCBI chr20:10,218,830...10,307,418
Ensembl chr20:10,172,395...10,308,258 		JBrowse link
G TRPV1 transient receptor potential cation channel subfamily V member 1 multiple interactions ISO
EXP		 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP promotes the reaction [Capsaicin results in increased activity of TRPV1] CTD PMID:12886029 NCBI chr17:3,565,446...3,609,411
Ensembl chr17:3,565,444...3,609,411 		JBrowse link
G VIP vasoactive intestinal peptide increases expression EXP 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of VIP mRNA CTD PMID:2156696 NCBI chr 6:152,750,797...152,759,760
Ensembl chr 6:152,750,797...152,759,765 		JBrowse link
8-(4-chlorophenylthio)-cGMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ALOX15 arachidonate 15-lipoxygenase increases expression EXP 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 protein CTD PMID:16166323 NCBI chr17:4,630,919...4,641,678
Ensembl chr17:4,630,919...4,642,294 		JBrowse link
G ARHGEF17 Rho guanine nucleotide exchange factor 17 multiple interactions EXP 2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein] CTD PMID:23195829 NCBI chr11:73,308,276...73,369,388
Ensembl chr11:73,308,276...73,369,388 		JBrowse link
G CEBPB CCAAT enhancer binding protein beta increases expression
multiple interactions		 ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein
8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein]		 CTD PMID:20471953 NCBI chr20:50,190,583...50,192,690
Ensembl chr20:50,190,830...50,192,668 		JBrowse link
G FABP4 fatty acid binding protein 4 increases expression
multiple interactions		 ISO 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein
8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein]		 CTD PMID:20471953 NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236 		JBrowse link
G NPPA natriuretic peptide A multiple interactions ISO [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] CTD PMID:11799084 NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345 		JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions
increases expression		 ISO 8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of PPARG protein] CTD PMID:20471953 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356 		JBrowse link
G PRKG1 protein kinase cGMP-dependent 1 multiple interactions
decreases expression
increases activity		 EXP
ISO		 2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein alternative form
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of PRKG1 protein
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]		 CTD PMID:9366573 PMID:11799084 PMID:23195829 NCBI chr10:50,990,888...52,298,350
Ensembl chr10:50,990,888...52,298,423 		JBrowse link
G RHOA ras homolog family member A multiple interactions EXP [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein] CTD PMID:23195829 NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998 		JBrowse link
G SCNN1A sodium channel epithelial 1 subunit alpha multiple interactions EXP 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] CTD PMID:19359370 NCBI chr12:6,346,847...6,377,359
Ensembl chr12:6,346,843...6,377,730 		JBrowse link
G SCNN1B sodium channel epithelial 1 subunit beta multiple interactions EXP 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] CTD PMID:19359370 NCBI chr16:23,278,231...23,381,294
Ensembl chr16:23,278,231...23,381,294 		JBrowse link
G SCNN1D sodium channel epithelial 1 subunit delta multiple interactions EXP 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] CTD PMID:19359370 NCBI chr 1:1,280,436...1,292,025
Ensembl chr 1:1,280,436...1,292,029 		JBrowse link
G SCNN1G sodium channel epithelial 1 subunit gamma multiple interactions EXP 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] CTD PMID:19359370 NCBI chr16:23,182,745...23,216,883
Ensembl chr16:23,182,745...23,216,883 		JBrowse link
G SRF serum response factor multiple interactions EXP [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein CTD PMID:23195829 NCBI chr 6:43,171,269...43,181,506
Ensembl chr 6:43,171,269...43,181,506 		JBrowse link
G VASP vasodilator stimulated phosphoprotein increases phosphorylation
decreases phosphorylation		 EXP
ISO		 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased phosphorylation of VASP protein
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased phosphorylation of VASP protein		 CTD PMID:11799084 PMID:16166323 NCBI chr19:45,507,479...45,526,983
Ensembl chr19:45,506,579...45,526,983 		JBrowse link
8-Br-cAMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCA1 ATP binding cassette subfamily A member 1 increases expression EXP
ISO		 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABCA1 protein CTD PMID:17478430 NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155 		JBrowse link
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA] CTD PMID:27743861 NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324 		JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCC1 mRNA CTD PMID:22079614 NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257 		JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA] CTD PMID:27743861 NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594 		JBrowse link
G ABCD2 ATP binding cassette subfamily D member 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCD2 mRNA CTD PMID:22079614 NCBI chr12:39,531,025...39,619,803
Ensembl chr12:39,550,033...39,619,803 		JBrowse link
G ABCG1 ATP binding cassette subfamily G member 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCG1 mRNA CTD PMID:22079614 NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244 		JBrowse link
G ABCG2 ATP binding cassette subfamily G member 2 (Junior blood group) multiple interactions EXP 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] CTD PMID:30610963 NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628 		JBrowse link
G ABLIM1 actin binding LIM protein 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABLIM1 mRNA CTD PMID:22079614 NCBI chr10:114,431,110...114,801,373
Ensembl chr10:114,431,112...114,768,061 		JBrowse link
G ABLIM2 actin binding LIM protein family member 2 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABLIM2 mRNA CTD PMID:22079614 NCBI chr 4:7,965,327...8,158,813
Ensembl chr 4:7,965,310...8,158,832 		JBrowse link
G ACAT2 acetyl-CoA acetyltransferase 2 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACAT2 mRNA CTD PMID:22079614 NCBI chr 6:159,762,045...159,779,112
Ensembl chr 6:159,762,045...159,779,112 		JBrowse link
G ACE2 angiotensin converting enzyme 2 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACE2 mRNA CTD PMID:22079614 NCBI chr  X:15,518,197...15,607,211
Ensembl chr  X:15,494,566...15,607,236 		JBrowse link
G ACP3 acid phosphatase 3 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ACP3 mRNA CTD PMID:22079614 NCBI chr 3:132,317,407...132,368,302
Ensembl chr 3:132,317,369...132,368,298 		JBrowse link
G ADAMTS6 ADAM metallopeptidase with thrombospondin type 1 motif 6 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADAMTS6 mRNA CTD PMID:20147733 PMID:22079614 NCBI chr 5:65,148,738...65,481,920
Ensembl chr 5:65,148,738...65,481,920 		JBrowse link
G ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif 8 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADAMTS8 mRNA CTD PMID:22079614 NCBI chr11:130,404,923...130,428,609
Ensembl chr11:130,404,923...130,428,609 		JBrowse link
G ADCY7 adenylate cyclase 7 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADCY7 mRNA CTD PMID:22079614 NCBI chr16:50,244,699...50,318,135
Ensembl chr16:50,246,137...50,318,135 		JBrowse link
G ADGRD1 adhesion G protein-coupled receptor D1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRD1 mRNA CTD PMID:22079614 NCBI chr12:130,953,907...131,141,469
Ensembl chr12:130,953,907...131,141,469 		JBrowse link
G ADGRG1 adhesion G protein-coupled receptor G1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRG1 mRNA CTD PMID:22079614 NCBI chr16:57,619,738...57,665,567
Ensembl chr16:57,610,652...57,665,580 		JBrowse link
G ADGRG2 adhesion G protein-coupled receptor G2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADGRG2 mRNA CTD PMID:22079614 NCBI chr  X:18,989,307...19,122,956
Ensembl chr  X:18,989,307...19,122,637 		JBrowse link
G ADRA2A adrenoceptor alpha 2A decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADRA2A mRNA CTD PMID:22079614 NCBI chr10:111,077,029...111,080,907
Ensembl chr10:111,077,029...111,080,907 		JBrowse link
G AGR2 anterior gradient 2, protein disulphide isomerase family member multiple interactions EXP [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AGR2 mRNA CTD PMID:16997883 NCBI chr 7:16,791,811...16,804,999
Ensembl chr 7:16,791,811...16,833,433 		JBrowse link
G AGT angiotensinogen decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGT mRNA CTD PMID:22079614 NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576 		JBrowse link
G AGTR1 angiotensin II receptor type 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGTR1 mRNA CTD PMID:22079614 NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008 		JBrowse link
G AHR aryl hydrocarbon receptor increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AHR mRNA CTD PMID:22079614 NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152 		JBrowse link
G AIFM1 apoptosis inducing factor mitochondria associated 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AIFM1 mRNA CTD PMID:22079614 NCBI chr  X:130,129,362...130,165,841
Ensembl chr  X:130,124,666...130,165,879 		JBrowse link
G AKAP7 A-kinase anchoring protein 7 multiple interactions EXP [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AKAP7 mRNA CTD PMID:16997883 NCBI chr 6:131,125,627...131,283,532
Ensembl chr 6:131,135,467...131,283,535 		JBrowse link
G AKAP9 A-kinase anchoring protein 9 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKAP9 mRNA CTD PMID:22079614 NCBI chr 7:91,940,862...92,110,673
Ensembl chr 7:91,940,840...92,110,673 		JBrowse link
G AKT1 AKT serine/threonine kinase 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKT1 mRNA CTD PMID:22079614 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751 		JBrowse link
G ALB albumin decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALB mRNA CTD PMID:22079614 NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482 		JBrowse link
G ALDH1A1 aldehyde dehydrogenase 1 family member A1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALDH1A1 mRNA CTD PMID:22079614 NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442 		JBrowse link
G ANGPT1 angiopoietin 1 multiple interactions EXP [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ANGPT1 mRNA CTD PMID:16997883 NCBI chr 8:107,249,482...107,497,918
Ensembl chr 8:107,249,482...107,498,055 		JBrowse link
G ANGPTL1 angiopoietin like 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ANGPTL1 mRNA CTD PMID:22079614 NCBI chr 1:178,849,535...178,871,077
Ensembl chr 1:178,849,535...178,871,077 		JBrowse link
G ANKH ANKH inorganic pyrophosphate transport regulator increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ANKH mRNA CTD PMID:20147733 NCBI chr 5:14,704,800...14,871,778
Ensembl chr 5:14,704,800...14,871,778 		JBrowse link
G ANKRD20A2P ankyrin repeat domain 20 family member A2, pseudogene decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ANKRD20A2P mRNA CTD PMID:22079614 NCBI chr 9:40,222,102...40,282,358
Ensembl chr 9:40,223,285...40,266,845 		JBrowse link
G ANXA8 annexin A8 multiple interactions EXP [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of ANXA8 mRNA CTD PMID:16997883 NCBI chr10:47,467,993...47,991,796
Ensembl chr10:47,460,162...47,484,158 		JBrowse link
G AOPEP aminopeptidase O (putative) decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AOPEP mRNA CTD PMID:22079614 NCBI chr 9:94,726,699...95,150,224
Ensembl chr 9:94,726,699...95,087,159 		JBrowse link
G APAF1 apoptotic peptidase activating factor 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APAF1 mRNA CTD PMID:22079614 NCBI chr12:98,645,290...98,735,433
Ensembl chr12:98,645,290...98,735,433 		JBrowse link
G APBB1IP amyloid beta precursor protein binding family B member 1 interacting protein increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of APBB1IP mRNA CTD PMID:22079614 NCBI chr10:26,438,341...26,567,803
Ensembl chr10:26,438,341...26,567,803 		JBrowse link
G APC APC regulator of WNT signaling pathway decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APC mRNA CTD PMID:22079614 NCBI chr 5:112,707,498...112,846,239
Ensembl chr 5:112,707,498...112,846,239 		JBrowse link
G APCDD1 APC down-regulated 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APCDD1 mRNA CTD PMID:22079614 NCBI chr18:10,454,635...10,489,949
Ensembl chr18:10,454,635...10,489,949 		JBrowse link
G AR androgen receptor decreases expression
multiple interactions		 EXP
ISO		 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AR mRNA
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA]		 CTD PMID:18467523 PMID:22079614 NCBI chr  X:67,544,021...67,730,619
Ensembl chr  X:67,544,021...67,730,619 		JBrowse link
G AREG amphiregulin increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AREG mRNA CTD PMID:20147733 PMID:22079614 NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005 		JBrowse link
G ARHGEF2 Rho/Rac guanine nucleotide exchange factor 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARHGEF2 mRNA CTD PMID:22079614 NCBI chr 1:155,946,854...155,979,617
Ensembl chr 1:155,946,851...156,007,070 		JBrowse link
G ARHGEF4 Rho guanine nucleotide exchange factor 4 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARHGEF4 mRNA CTD PMID:22079614 NCBI chr 2:130,836,914...131,047,253
Ensembl chr 2:130,836,914...131,047,263 		JBrowse link
G ARID5B AT-rich interaction domain 5B decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARID5B mRNA CTD PMID:22079614 NCBI chr10:61,901,699...62,096,944
Ensembl chr10:61,901,684...62,096,944 		JBrowse link
G ARMCX3 armadillo repeat containing X-linked 3 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX3 mRNA CTD PMID:22079614 NCBI chr  X:101,623,151...101,627,843
Ensembl chr  X:101,622,797...101,627,843 		JBrowse link
G ARMCX4 armadillo repeat containing X-linked 4 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX4 mRNA CTD PMID:22079614 NCBI chr  X:101,418,278...101,535,988
Ensembl chr  X:101,418,287...101,533,459 		JBrowse link
G ASNS asparagine synthetase (glutamine-hydrolyzing) increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ASNS mRNA CTD PMID:22079614 NCBI chr 7:97,851,677...97,928,441
Ensembl chr 7:97,851,677...97,872,542 		JBrowse link
G ATP4A ATPase H+/K+ transporting subunit alpha increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ATP4A mRNA CTD PMID:22079614 NCBI chr19:35,550,031...35,563,658
Ensembl chr19:35,550,031...35,563,658 		JBrowse link
G AVPI1 arginine vasopressin induced 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AVPI1 mRNA CTD PMID:22079614 NCBI chr10:97,677,424...97,687,241
Ensembl chr10:97,677,424...97,687,241 		JBrowse link
G B4GALNT3 beta-1,4-N-acetyl-galactosaminyltransferase 3 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of B4GALNT3 mRNA CTD PMID:22079614 NCBI chr12:459,939...563,509
Ensembl chr12:459,939...563,509 		JBrowse link
G BANK1 B cell scaffold protein with ankyrin repeats 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BANK1 mRNA CTD PMID:22079614 NCBI chr 4:101,790,730...102,074,812
Ensembl chr 4:101,411,286...102,074,812 		JBrowse link
G BAX BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BAX
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BAX protein		 CTD PMID:11802967 PMID:16709600 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798 		JBrowse link
G BCAT1 branched chain amino acid transaminase 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BCAT1 mRNA CTD PMID:22079614 NCBI chr12:24,810,024...24,949,101
Ensembl chr12:24,810,024...24,949,101 		JBrowse link
G BCL2 BCL2 apoptosis regulator decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BCL2 CTD PMID:11802967 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G BCL2L11 BCL2 like 11 multiple interactions EXP [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein CTD PMID:16709600 NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,445 		JBrowse link
G BDKRB1 bradykinin receptor B1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB1 mRNA CTD PMID:20147733 NCBI chr14:96,256,210...96,264,763
Ensembl chr14:96,256,210...96,268,967 		JBrowse link
G BDKRB2 bradykinin receptor B2 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB2 mRNA CTD PMID:20147733 NCBI chr14:96,204,839...96,244,164
Ensembl chr14:96,204,679...96,244,166 		JBrowse link
G BMP4 bone morphogenetic protein 4 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP4 mRNA CTD PMID:22079614 NCBI chr14:53,949,736...53,956,891
Ensembl chr14:53,949,736...53,958,761 		JBrowse link
G BMP6 bone morphogenetic protein 6 decreases expression
increases expression		 EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP6 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BMP6 mRNA		 CTD PMID:20147733 PMID:22079614 NCBI chr 6:7,726,099...7,881,728
Ensembl chr 6:7,726,099...7,881,728 		JBrowse link
G BRINP1 BMP/retinoic acid inducible neural specific 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BRINP1 mRNA CTD PMID:20147733 NCBI chr 9:119,166,629...119,369,435
Ensembl chr 9:119,153,458...119,369,435 		JBrowse link
G BTBD9 BTB domain containing 9 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BTBD9 mRNA CTD PMID:22079614 NCBI chr 6:38,168,451...38,639,929
Ensembl chr 6:38,168,451...38,640,148 		JBrowse link
G CABLES1 Cdk5 and Abl enzyme substrate 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABLES1 mRNA CTD PMID:22079614 NCBI chr18:23,134,564...23,260,470
Ensembl chr18:23,134,564...23,260,470 		JBrowse link
G CABP7 calcium binding protein 7 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABP7 mRNA CTD PMID:22079614 NCBI chr22:29,720,003...29,731,833
Ensembl chr22:29,720,003...29,731,833 		JBrowse link
G CADM1 cell adhesion molecule 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CADM1 mRNA CTD PMID:22079614 NCBI chr11:115,169,236...115,504,415
Ensembl chr11:115,169,218...115,504,957 		JBrowse link
G CADM2 cell adhesion molecule 2 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CADM2 mRNA CTD PMID:22079614 NCBI chr 3:84,958,989...86,074,429
Ensembl chr 3:84,958,989...86,074,429 		JBrowse link
G CALN1 calneuron 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CALN1 mRNA CTD PMID:22079614 NCBI chr 7:71,779,491...72,504,279
Ensembl chr 7:71,779,491...72,447,151 		JBrowse link
G CALR calreticulin increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CALR mRNA CTD PMID:22079614 NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489 		JBrowse link
G CAMK2N1 calcium/calmodulin dependent protein kinase II inhibitor 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAMK2N1 mRNA CTD PMID:22079614 NCBI chr 1:20,482,391...20,486,210
Ensembl chr 1:20,482,391...20,486,210 		JBrowse link
G CAPN15 calpain 15 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CAPN15 mRNA CTD PMID:22079614 NCBI chr16:527,712...554,636
Ensembl chr16:527,712...554,636 		JBrowse link
G CAPN2 calpain 2 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN2 mRNA CTD PMID:22079614 NCBI chr 1:223,701,597...223,776,018
Ensembl chr 1:223,701,593...223,776,018 		JBrowse link
G CAPN6 calpain 6 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN6 mRNA CTD PMID:22079614 NCBI chr  X:111,245,099...111,270,483
Ensembl chr  X:111,245,099...111,270,483 		JBrowse link
G CARD14 caspase recruitment domain family member 14 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARD14 mRNA CTD PMID:22079614 NCBI chr17:80,170,030...80,209,331
Ensembl chr17:80,169,992...80,209,331 		JBrowse link
G CARS1 cysteinyl-tRNA synthetase 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARS1 mRNA CTD PMID:22079614 NCBI chr11:3,000,929...3,057,423
Ensembl chr11:3,000,922...3,057,613 		JBrowse link
G CASP3 caspase 3 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CASP3 mRNA CTD PMID:22079614 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509 		JBrowse link
G CASP9 caspase 9 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CASP9 mRNA CTD PMID:22079614 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534 		JBrowse link
G CAT catalase multiple interactions EXP [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CAT mRNA CTD PMID:16709600 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CBR4 carbonyl reductase 4 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CBR4 mRNA CTD PMID:22079614 NCBI chr 4:168,894,486...169,010,255
Ensembl chr 4:168,863,770...169,010,275 		JBrowse link
G CCDC170 coiled-coil domain containing 170 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC170 mRNA CTD PMID:22079614 NCBI chr 6:151,494,017...151,621,193
Ensembl chr 6:151,494,017...151,621,193 		JBrowse link
G CCDC3 coiled-coil domain containing 3 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCDC3 mRNA CTD PMID:22079614 NCBI chr10:12,896,625...13,099,989
Ensembl chr10:12,896,625...13,099,652 		JBrowse link
G CCDC80 coiled-coil domain containing 80 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC80 mRNA CTD PMID:22079614 NCBI chr 3:112,596,797...112,641,143
Ensembl chr 3:112,596,797...112,649,530 		JBrowse link
G CCL2 C-C motif chemokine ligand 2 multiple interactions
increases expression		 EXP
ISO		 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]]; [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CCL2 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCL2 protein		 CTD PMID:11230753 PMID:16997883 PMID:20940016 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208 		JBrowse link
G CCL5 C-C motif chemokine ligand 5 multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] CTD PMID:10495789 NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793 		JBrowse link
G CCN3 cellular communication network factor 3 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN3 mRNA CTD PMID:22079614 NCBI chr 8:119,416,446...119,424,434
Ensembl chr 8:119,416,446...119,424,434 		JBrowse link
G CCN6 cellular communication network factor 6 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN6 mRNA CTD PMID:22079614 NCBI chr 6:112,052,813...112,069,686
Ensembl chr 6:112,054,075...112,069,686 		JBrowse link
G CCNA1 cyclin A1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCNA1 mRNA CTD PMID:22079614 NCBI chr13:36,431,517...36,442,870
Ensembl chr13:36,431,520...36,442,870 		JBrowse link
G CCND2 cyclin D2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCND2 mRNA CTD PMID:22079614 NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353 		JBrowse link
G CD244 CD244 molecule increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD244 mRNA CTD PMID:22079614 NCBI chr 1:160,830,160...160,862,887
Ensembl chr 1:160,830,160...160,862,887 		JBrowse link
G CD74 CD74 molecule increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD74 mRNA CTD PMID:22079614 NCBI chr 5:150,401,639...150,412,910
Ensembl chr 5:150,401,637...150,412,969 		JBrowse link
G CD9 CD9 molecule increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD9 mRNA CTD PMID:22079614 NCBI chr12:6,199,946...6,238,266
Ensembl chr12:6,199,715...6,238,271 		JBrowse link
G CDH1 cadherin 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH1 protein CTD PMID:32028606 NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537 		JBrowse link
G CDH22 cadherin 22 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH22 mRNA CTD PMID:22079614 NCBI chr20:46,173,739...46,308,498
Ensembl chr20:46,173,739...46,308,498 		JBrowse link
G CDH4 cadherin 4 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH4 mRNA CTD PMID:22079614 NCBI chr20:61,252,261...61,940,617
Ensembl chr20:61,252,261...61,940,617 		JBrowse link
G CDH6 cadherin 6 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDH6 mRNA CTD PMID:22079614 NCBI chr 5:31,193,686...31,329,146
Ensembl chr 5:31,193,686...31,329,146 		JBrowse link
G CDK2 cyclin dependent kinase 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDK2 mRNA CTD PMID:22079614 NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789 		JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDKN1A mRNA CTD PMID:22079614 NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337 		JBrowse link
G CDON cell adhesion associated, oncogene regulated increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDON mRNA CTD PMID:20147733 NCBI chr11:125,956,821...126,063,352
Ensembl chr11:125,955,796...126,063,335 		JBrowse link
G CDX1 caudal type homeobox 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDX1 mRNA CTD PMID:22079614 NCBI chr 5:150,166,778...150,184,558
Ensembl chr 5:150,166,778...150,184,558 		JBrowse link
G CEACAM6 CEA cell adhesion molecule 6 multiple interactions EXP [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEACAM6 mRNA CTD PMID:16997883 NCBI chr19:41,755,530...41,772,211
Ensembl chr19:41,750,977...41,772,211 		JBrowse link
G CEBPG CCAAT enhancer binding protein gamma increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CEBPG mRNA CTD PMID:22079614 NCBI chr19:33,373,709...33,382,686
Ensembl chr19:33,373,685...33,382,686 		JBrowse link
G CFLAR CASP8 and FADD like apoptosis regulator multiple interactions EXP [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CFLAR protein alternative form CTD PMID:16709600 NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687 		JBrowse link
G CGA glycoprotein hormones, alpha polypeptide increases expression ISO
EXP		 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGA mRNA CTD PMID:8404651 PMID:21467749 PMID:22079614 NCBI chr 6:87,085,498...87,095,106
Ensembl chr 6:87,085,498...87,095,106 		JBrowse link
G CGN cingulin increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGN mRNA CTD PMID:22079614 NCBI chr 1:151,510,170...151,538,692
Ensembl chr 1:151,510,510...151,538,692 		JBrowse link
G CHN1 chimerin 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CHN1 mRNA CTD PMID:22079614 NCBI chr 2:174,798,809...175,005,381
Ensembl chr 2:174,798,809...175,005,381 		JBrowse link
G CHP1 calcineurin like EF-hand protein 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CHP1 mRNA CTD PMID:22079614 NCBI chr15:41,231,268...41,281,887
Ensembl chr15:41,230,839...41,281,887 		JBrowse link
G CIDEA cell death inducing DFFA like effector a increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEA mRNA CTD PMID:22079614 NCBI chr18:12,254,361...12,277,595
Ensembl chr18:12,254,361...12,277,595 		JBrowse link
G CIDEC cell death inducing DFFA like effector c increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEC protein CTD PMID:21097823 NCBI chr 3:9,866,710...9,880,253
Ensembl chr 3:9,866,711...9,880,255 		JBrowse link
G CKMT2 creatine kinase, mitochondrial 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CKMT2 mRNA CTD PMID:22079614 NCBI chr 5:81,233,322...81,266,398
Ensembl chr 5:81,233,320...81,266,398 		JBrowse link
G CLDN1 claudin 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CLDN1 mRNA CTD PMID:22079614 NCBI chr 3:190,305,707...190,322,446
Ensembl chr 3:190,305,707...190,322,446 		JBrowse link
G CLDN5 claudin 5 increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLDN5 mRNA CTD PMID:20711499 NCBI chr22:19,523,024...19,525,337
Ensembl chr22:19,523,024...19,527,545 		JBrowse link
G CLGN calmegin increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLGN mRNA CTD PMID:20147733 PMID:22079614 NCBI chr 4:140,388,453...140,427,648
Ensembl chr 4:140,388,453...140,427,661 		JBrowse link
G CLIC3 chloride intracellular channel 3 multiple interactions
increases expression		 EXP [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CLIC3 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLIC3 mRNA		 CTD PMID:16997883 PMID:22079614 NCBI chr 9:136,994,608...136,996,568
Ensembl chr 9:136,994,608...136,996,568 		JBrowse link
G CMKLR1 chemerin chemokine-like receptor 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CMKLR1 mRNA CTD PMID:20147733 NCBI chr12:108,288,046...108,339,311
Ensembl chr12:108,288,044...108,339,317 		JBrowse link
G CNIH3 cornichon family AMPA receptor auxiliary protein 3 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNIH3 mRNA CTD PMID:22079614 NCBI chr 1:224,434,640...224,740,554
Ensembl chr 1:224,434,660...224,740,554 		JBrowse link
G CNR1 cannabinoid receptor 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNR1 mRNA CTD PMID:22079614 NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347 		JBrowse link
G COL15A1 collagen type XV alpha 1 chain multiple interactions EXP [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL15A1 mRNA CTD PMID:16997883 NCBI chr 9:98,911,204...99,070,787
Ensembl chr 9:98,943,179...99,070,792 		JBrowse link
G COL4A4 collagen type IV alpha 4 chain decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL4A4 mRNA CTD PMID:22079614 NCBI chr 2:226,967,360...227,164,488
Ensembl chr 2:227,002,714...227,164,453 		JBrowse link
G COL4A6 collagen type IV alpha 6 chain multiple interactions EXP [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL4A6 mRNA CTD PMID:16997883 NCBI chr  X:108,155,614...108,439,458
Ensembl chr  X:108,155,607...108,439,497 		JBrowse link
G COL6A3 collagen type VI alpha 3 chain decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL6A3 mRNA CTD PMID:22079614 NCBI chr 2:237,324,018...237,414,164
Ensembl chr 2:237,324,003...237,414,328 		JBrowse link
G COL7A1 collagen type VII alpha 1 chain multiple interactions EXP [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL7A1 mRNA CTD PMID:16997883 NCBI chr 3:48,564,073...48,595,329
Ensembl chr 3:48,564,073...48,595,329 		JBrowse link
G COLEC12 collectin subfamily member 12 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of COLEC12 mRNA CTD PMID:22079614 NCBI chr18:316,737...500,701
Ensembl chr18:316,737...500,722 		JBrowse link
G CORO2A coronin 2A decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CORO2A mRNA CTD PMID:22079614 NCBI chr 9:98,120,975...98,192,637
Ensembl chr 9:98,120,975...98,192,637 		JBrowse link
G CPM carboxypeptidase M decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CPM mRNA CTD PMID:22079614 NCBI chr12:68,842,197...68,963,469
Ensembl chr12:68,842,197...68,971,570 		JBrowse link
G CPO carboxypeptidase O increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CPO mRNA CTD PMID:22079614 NCBI chr 2:206,939,518...206,969,474
Ensembl chr 2:206,939,518...206,969,474 		JBrowse link
G CRADD CASP2 and RIPK1 domain containing adaptor with death domain increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CRADD mRNA CTD PMID:22079614 NCBI chr12:93,677,375...93,894,840
Ensembl chr12:93,677,375...93,894,840 		JBrowse link
G CREB1 cAMP responsive element binding protein 1 multiple interactions ISO [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of CREB1 protein CTD PMID:18467523 NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988 		JBrowse link
G CRH corticotropin releasing hormone multiple interactions ISO 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]] CTD PMID:2153673 NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464 		JBrowse link
G CRHBP corticotropin releasing hormone binding protein decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CRHBP mRNA CTD PMID:22079614 NCBI chr 5:76,953,045...76,981,159
Ensembl chr 5:76,953,045...76,981,158 		JBrowse link
G CST6 cystatin E/M multiple interactions EXP [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CST6 mRNA CTD PMID:16997883 NCBI chr11:66,012,008...66,013,505
Ensembl chr11:66,012,008...66,013,505 		JBrowse link
G CTAGE1 cutaneous T cell lymphoma-associated antigen 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTAGE1 mRNA CTD PMID:22079614 NCBI chr18:22,413,599...22,417,915
Ensembl chr18:22,413,599...22,417,915 		JBrowse link
G CTNNA2 catenin alpha 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTNNA2 mRNA CTD PMID:22079614 NCBI chr 2:79,185,377...80,648,780
Ensembl chr 2:79,185,231...80,648,861 		JBrowse link
G CTTNBP2 cortactin binding protein 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTTNBP2 mRNA CTD PMID:22079614 NCBI chr 7:117,710,651...117,873,441
Ensembl chr 7:117,710,651...117,874,139 		JBrowse link
G CUX2 cut like homeobox 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CUX2 mRNA CTD PMID:22079614 NCBI chr12:111,034,165...111,350,554
Ensembl chr12:111,034,165...111,350,554 		JBrowse link
G CX3CL1 C-X3-C motif chemokine ligand 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CX3CL1 mRNA CTD PMID:22079614 NCBI chr16:57,372,490...57,385,044
Ensembl chr16:57,372,477...57,385,044 		JBrowse link
G CXCL10 C-X-C motif chemokine ligand 10 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL10 mRNA CTD PMID:22079614 NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497 		JBrowse link
G CXCL12 C-X-C motif chemokine ligand 12 decreases expression
increases expression		 ISO
EXP		 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CXCL12 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL12 mRNA		 CTD PMID:20711499 PMID:22079614 NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions
increases expression		 EXP daidzein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL8 mRNA]; Estradiol inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL8 mRNA]; Genistein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL8 mRNA] CTD PMID:21056929 PMID:22079614 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716 		JBrowse link
G CYCS cytochrome c, somatic decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYCS mRNA CTD PMID:22079614 NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260 		JBrowse link
G CYP11A1 cytochrome P450 family 11 subfamily A member 1 multiple interactions
increases expression
increases activity		 ISO
EXP		 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein
Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein]		 CTD PMID:20147733 PMID:21126571 PMID:21610156 PMID:21664964 PMID:21726595 More... NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646 		JBrowse link
G CYP11B1 cytochrome P450 family 11 subfamily B member 1 multiple interactions
increases expression		 EXP Mitotane affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B1 mRNA] CTD PMID:22079614 PMID:22172629 PMID:22546480 NCBI chr 8:142,872,357...142,879,825
Ensembl chr 8:142,872,356...142,879,846 		JBrowse link
G CYP11B2 cytochrome P450 family 11 subfamily B member 2 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B2 mRNA CTD PMID:22079614 NCBI chr 8:142,910,559...142,917,843
Ensembl chr 8:142,910,559...142,917,843 		JBrowse link
G CYP17A1 cytochrome P450 family 17 subfamily A member 1 multiple interactions
increases expression		 EXP
ISO		 [4-nitro-3-phenylphenol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of CYP17A1 protein; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP17A1 mRNA; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]		 CTD PMID:18336853 PMID:21610156 PMID:21726595 PMID:22079614 PMID:22546480 More... NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472 		JBrowse link
G CYP19A1 cytochrome P450 family 19 subfamily A member 1 multiple interactions
increases expression
increases activity		 ISO
EXP		 [vinclozolin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA]; bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; formestane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Methoxychlor inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]
[NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 protein		 CTD PMID:10746939 PMID:18815356 PMID:21126571 PMID:21610156 PMID:22120136 More... NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601 		JBrowse link
G CYP1B1 cytochrome P450 family 1 subfamily B member 1 increases expression EXP
ISO		 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 protein		 CTD PMID:7588239 PMID:22079614 NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902 		JBrowse link
G CYP21A2 cytochrome P450 family 21 subfamily A member 2 increases expression
multiple interactions		 EXP
ISO		 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP21A2 mRNA
[NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP21A1 mRNA
Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP21A2 mRNA]		 CTD PMID:21610156 PMID:22079614 PMID:22546480 NCBI chr 6:32,038,415...32,041,644
Ensembl chr 6:32,038,327...32,041,644 		JBrowse link
G CYP27A1 cytochrome P450 family 27 subfamily A member 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP27A1 mRNA CTD PMID:22079614 NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293 		JBrowse link
G CYP2E1 cytochrome P450 family 2 subfamily E member 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP2E1 mRNA CTD PMID:22079614 NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220 		JBrowse link
G CYP2F1 cytochrome P450 family 2 subfamily F member 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP2F1 mRNA CTD PMID:22079614 NCBI chr19:41,114,432...41,128,381
Ensembl chr19:41,114,432...41,128,381 		JBrowse link
G CYP3A5 cytochrome P450 family 3 subfamily A member 5 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP3A5 mRNA CTD PMID:22079614 NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,998 		JBrowse link
G CYP3A7 cytochrome P450 family 3 subfamily A member 7 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP3A7 mRNA CTD PMID:22079614 NCBI chr 7:99,705,036...99,735,196
Ensembl chr 7:99,705,036...99,735,196 		JBrowse link
G CYP51A1 cytochrome P450 family 51 subfamily A member 1 increases expression
multiple interactions		 EXP
ISO		 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP51A1 mRNA
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA; [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein]		 CTD PMID:18467523 PMID:22079614 NCBI chr 7:92,112,153...92,134,803
Ensembl chr 7:92,084,987...92,134,803 		JBrowse link
G CYP8B1 cytochrome P450 family 8 subfamily B member 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP8B1 mRNA CTD PMID:22079614 NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898 		JBrowse link
G CYTH1 cytohesin 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYTH1 mRNA CTD PMID:22079614 NCBI chr17:78,674,048...78,782,273
Ensembl chr17:78,674,048...78,782,297 		JBrowse link
G DACH2 dachshund family transcription factor 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACH2 mRNA CTD PMID:22079614 NCBI chr  X:86,148,451...86,832,602
Ensembl chr  X:86,148,451...86,832,604 		JBrowse link
G DACT1 dishevelled binding antagonist of beta catenin 1 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACT1 mRNA CTD PMID:22079614 NCBI chr14:58,634,061...58,648,321
Ensembl chr14:58,633,967...58,648,321 		JBrowse link
G DAZ2 deleted in azoospermia 2 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DAZ2 mRNA CTD PMID:22079614 NCBI chr  Y:23,219,457...23,291,356
Ensembl chr  Y:23,219,447...23,291,356 		JBrowse link
G DBIL5P diazepam binding inhibitor-like 5, pseudogene increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DBIL5P mRNA CTD PMID:22079614 NCBI chr17:752,333...755,336
Ensembl chr17:752,660...755,336 		JBrowse link
G DCAF12L1 DDB1 and CUL4 associated factor 12 like 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCAF12L1 mRNA CTD PMID:22079614 NCBI chr  X:126,549,383...126,552,814
Ensembl chr  X:126,549,383...126,552,814 		JBrowse link
G DCBLD2 discoidin, CUB and LCCL domain containing 2 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCBLD2 mRNA CTD PMID:22079614 NCBI chr 3:98,795,941...98,901,695
Ensembl chr 3:98,795,941...98,901,695 		JBrowse link
G DGAT2 diacylglycerol O-acyltransferase 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DGAT2 mRNA CTD PMID:22079614 NCBI chr11:75,768,778...75,801,534
Ensembl chr11:75,759,512...75,801,535 		JBrowse link
G DGKB diacylglycerol kinase beta increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DGKB mRNA CTD PMID:22079614 NCBI chr 7:14,145,049...14,974,858
Ensembl chr 7:14,145,049...14,974,777 		JBrowse link
G DHCR24 24-dehydrocholesterol reductase increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR24 mRNA CTD PMID:22079614 NCBI chr 1:54,849,627...54,887,195
Ensembl chr 1:54,849,627...54,887,195 		JBrowse link
G DHCR7 7-dehydrocholesterol reductase increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR7 mRNA CTD PMID:22079614 NCBI chr11:71,434,411...71,448,393
Ensembl chr11:71,428,193...71,452,868 		JBrowse link
G DHRS2 dehydrogenase/reductase 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DHRS2 mRNA CTD PMID:22079614 NCBI chr14:23,630,115...23,645,639
Ensembl chr14:23,630,115...23,645,639 		JBrowse link
G DHRS3 dehydrogenase/reductase 3 multiple interactions EXP 7-propyl spirolactone inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein; Aldosterone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA] CTD PMID:23275455 NCBI chr 1:12,567,910...12,618,210
Ensembl chr 1:12,567,910...12,618,210 		JBrowse link
G DIO2 iodothyronine deiodinase 2 multiple interactions
increases activity		 EXP
ISO		 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased activity of DIO2 protein
8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein
Acetylcysteine inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]]; Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]]		 CTD PMID:11425850 PMID:18420745 NCBI chr14:80,197,526...80,231,057
Ensembl chr14:80,197,526...80,387,757 		JBrowse link
G DIO3 iodothyronine deiodinase 3 multiple interactions ISO Acetylcysteine inhibits the reaction [[Hydrogen Peroxide co-treated with Sodium Selenite] promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein] CTD PMID:18420745 NCBI chr14:101,561,351...101,563,452
Ensembl chr14:101,561,351...101,563,452 		JBrowse link
G DKK1 dickkopf WNT signaling pathway inhibitor 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DKK1 mRNA CTD PMID:22079614 NCBI chr10:52,314,281...52,317,657
Ensembl chr10:52,314,281...52,318,042 		JBrowse link
G DLEU2 deleted in lymphocytic leukemia 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DLEU2 mRNA CTD PMID:22079614 NCBI chr13:49,982,549...50,125,541
Ensembl chr13:49,956,670...50,125,720 		JBrowse link
G DNAH5 dynein axonemal heavy chain 5 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAH5 mRNA CTD PMID:22079614 NCBI chr 5:13,690,328...14,011,818
Ensembl chr 5:13,690,328...14,011,818 		JBrowse link
G DNAJB3 DnaJ heat shock protein family (Hsp40) member B3 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DNAJB3 mRNA CTD PMID:22079614 NCBI chr 2:233,742,750...233,743,998
Ensembl chr 2:233,742,750...233,744,015 		JBrowse link
G DNAJB7 DnaJ heat shock protein family (Hsp40) member B7 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB7 mRNA CTD PMID:22079614 NCBI chr22:40,859,549...40,862,113
Ensembl chr22:40,859,549...40,862,113 		JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB9 mRNA CTD PMID:22079614 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850 		JBrowse link
G DNER delta/notch like EGF repeat containing increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNER mRNA CTD PMID:22079614 NCBI chr 2:229,357,629...229,714,555
Ensembl chr 2:229,357,629...229,714,555 		JBrowse link
G DOCK11 dedicator of cytokinesis 11 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOCK11 mRNA CTD PMID:22079614 NCBI chr  X:118,495,815...118,686,147
Ensembl chr  X:118,495,815...118,686,163 		JBrowse link
G DOK5 docking protein 5 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOK5 mRNA CTD PMID:22079614 NCBI chr20:54,475,593...54,651,169
Ensembl chr20:54,475,593...54,651,169 		JBrowse link
G DUSP1 dual specificity phosphatase 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP1 mRNA CTD PMID:22079614 NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195 		JBrowse link
G DUSP16 dual specificity phosphatase 16 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP16 mRNA CTD PMID:22079614 NCBI chr12:12,473,282...12,562,863
Ensembl chr12:12,473,282...12,562,863 		JBrowse link
G DUSP4 dual specificity phosphatase 4 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP4 mRNA CTD PMID:20147733 NCBI chr 8:29,333,064...29,350,684
Ensembl chr 8:29,333,064...29,350,684 		JBrowse link
G DUSP6 dual specificity phosphatase 6 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DUSP6 mRNA CTD PMID:22079614 NCBI chr12:89,347,235...89,352,501
Ensembl chr12:89,347,235...89,352,501 		JBrowse link
G EBP EBP cholestenol delta-isomerase increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EBP mRNA CTD PMID:22079614 NCBI chr  X:48,521,808...48,528,716
Ensembl chr  X:48,521,799...48,528,716 		JBrowse link
G ECHS1 enoyl-CoA hydratase, short chain 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ECHS1 mRNA CTD PMID:22079614 NCBI chr10:133,362,485...133,373,354
Ensembl chr10:133,362,485...133,373,354 		JBrowse link
G EGF epidermal growth factor multiple interactions ISO EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]] CTD PMID:18467523 NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766 		JBrowse link
G EGFR epidermal growth factor receptor increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGFR mRNA CTD PMID:22079614 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628 		JBrowse link
G EGR1 early growth response 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR1 mRNA CTD PMID:22079614 NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303 		JBrowse link
G EGR2 early growth response 2 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR2 mRNA CTD PMID:20147733 PMID:22079614 NCBI chr10:62,811,996...62,819,167
Ensembl chr10:62,811,996...62,819,167 		JBrowse link
G ELP1 elongator acetyltransferase complex subunit 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ELP1 mRNA CTD PMID:22079614 NCBI chr 9:108,867,517...108,934,124
Ensembl chr 9:108,866,898...108,934,328 		JBrowse link
G EMP2 epithelial membrane protein 2 multiple interactions
decreases expression		 EXP [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of EMP2 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EMP2 mRNA		 CTD PMID:16997883 PMID:22079614 NCBI chr16:10,528,422...10,580,598
Ensembl chr16:10,528,422...10,580,632 		JBrowse link
G ENOX1 ecto-NOX disulfide-thiol exchanger 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ENOX1 mRNA CTD PMID:20147733 NCBI chr13:43,213,130...43,786,972
Ensembl chr13:43,213,130...43,786,972 		JBrowse link
G EP300 E1A binding protein p300 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EP300 mRNA CTD PMID:22079614 NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,592...41,180,077 		JBrowse link
G EPG5 ectopic P-granules 5 autophagy tethering factor decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EPG5 mRNA CTD PMID:20147733 NCBI chr18:45,800,581...45,967,329
Ensembl chr18:45,800,581...45,967,329 		JBrowse link
G EPHX1 epoxide hydrolase 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EPHX1 mRNA CTD PMID:22079614 NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563 		JBrowse link
G ERAP1 endoplasmic reticulum aminopeptidase 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ERAP1 mRNA CTD PMID:22079614 NCBI chr 5:96,760,813...96,935,854
Ensembl chr 5:96,760,810...96,808,100 		JBrowse link
G ERF ETS2 repressor factor decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ERF mRNA CTD PMID:22079614 NCBI chr19:42,247,569...42,255,128
Ensembl chr19:42,247,569...42,255,128 		JBrowse link
G ESR2 estrogen receptor 2 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESR2 mRNA CTD PMID:22079614 NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112 		JBrowse link
G ESRRA estrogen related receptor alpha increases expression ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ESRRA mRNA CTD PMID:23166782 NCBI chr11:64,305,524...64,316,743
Ensembl chr11:64,305,497...64,316,743 		JBrowse link
G ESRRG estrogen related receptor gamma decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESRRG mRNA CTD PMID:22079614 NCBI chr 1:216,503,246...217,137,702
Ensembl chr 1:216,503,246...217,137,755 		JBrowse link
G ETNPPL ethanolamine-phosphate phospho-lyase increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETNPPL mRNA CTD PMID:22079614 NCBI chr 4:108,742,053...108,763,053
Ensembl chr 4:108,742,048...108,763,054 		JBrowse link
G ETV1 ETS variant transcription factor 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETV1 mRNA CTD PMID:20147733 NCBI chr 7:13,891,229...13,991,425
Ensembl chr 7:13,891,229...13,991,425 		JBrowse link
G ETV5 ETS variant transcription factor 5 decreases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ETV5 mRNA CTD PMID:22079614 NCBI chr 3:186,046,314...186,109,089
Ensembl chr 3:186,046,314...186,110,318 		JBrowse link
G EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit decreases expression
multiple interactions		 EXP 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 protein
[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA]		 CTD PMID:21903722 NCBI chr 7:148,807,383...148,884,291
Ensembl chr 7:148,807,257...148,884,321 		JBrowse link
G F2RL2 coagulation factor II thrombin receptor like 2 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of F2RL2 mRNA CTD PMID:20147733 NCBI chr 5:76,615,482...76,623,403
Ensembl chr 5:76,615,482...76,623,413 		JBrowse link
G FABP1 fatty acid binding protein 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FABP1 mRNA CTD PMID:22079614 NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062 		JBrowse link
G FADS1 fatty acid desaturase 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FADS1 mRNA CTD PMID:22079614 NCBI chr11:61,799,627...61,817,003
Ensembl chr11:61,799,627...61,829,318 		JBrowse link
G FASLG Fas ligand multiple interactions EXP [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FASLG protein CTD PMID:16709600 NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876 		JBrowse link
G FBLN1 fibulin 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FBLN1 mRNA CTD PMID:15774544 NCBI chr22:45,502,883...45,601,135
Ensembl chr22:45,502,238...45,601,135 		JBrowse link
G FBXO32 F-box protein 32 multiple interactions EXP [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA] CTD PMID:23275455 NCBI chr 8:123,497,889...123,541,206
Ensembl chr 8:123,497,889...123,541,206 		JBrowse link
G FDFT1 farnesyl-diphosphate farnesyltransferase 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDFT1 mRNA CTD PMID:22079614 NCBI chr 8:11,795,582...11,839,309
Ensembl chr 8:11,795,573...11,839,304 		JBrowse link
G FDX1 ferredoxin 1 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDX1 mRNA CTD PMID:22079614 NCBI chr11:110,429,331...110,464,884
Ensembl chr11:110,429,948...110,464,884 		JBrowse link
G FDXR ferredoxin reductase increases expression
multiple interactions		 ISO 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein
Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein]		 CTD PMID:24740604 NCBI chr17:74,862,497...74,872,994
Ensembl chr17:74,862,497...74,873,031 		JBrowse link
G FER1L6 fer-1 like family member 6 increases expression EXP 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FER1L6 mRNA CTD PMID:20147733 NCBI chr 8:123,851,987...124,120,061
Ensembl chr 8:123,851,987...124,120,061 		JBrowse link
G